Document:

EX-10.1

 EXHIBIT 10.1 
 AMENDMENT NO. 1 TO CREDIT AGREEMENT 
 THIS AMENDMENT NO. 1 TO THE
CREDIT AGREEMENT, dated as of August 1, 2012 (this “Amendment”) among GENERAL CABLE INDUSTRIES, INC., a Delaware corporation (the “U.S. Borrower”), GENERAL CABLE COMPANY, an unlimited company organized under
the laws of Nova Scotia (the “Canadian Borrower” and, together with the U.S. Borrower, collectively, the “Borrowers” and each individually, a “Borrower”), the other loan parties party hereto, the
Lenders party hereto, the Issuing Banks, the Swingline Lenders, JPMORGAN CHASE BANK, N.A., as Administrative Agent, and WELLS FARGO BANK, N.A. and CREDIT AGRICOLE CORPORATE AND INVESTMENT BANK, as joint lead arrangers, joint bookrunners and
co-syndication agents. Each capitalized term used herein and not defined herein shall have the meaning ascribed thereto in the Credit Agreement referred to below. 
 WITNESSETH 
 WHEREAS, the Borrowers, the Lenders, the Administrative Agent and
certain other Persons are parties to that certain Credit Agreement, dated as of July 21, 2011 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”); 

WHEREAS, Holdings, through one of more of its Subsidiaries, intends to (a) purchase (i) all of the Equity Interests of certain
direct and indirect subsidiaries organized, established or incorporated, as the case may be, under the laws of certain States of the United States and Mexico, as applicable, of Rio Tinto plc, a company incorporated in England with registered number
719885 (ii) certain assets of Rio Tinto Alcan Inc., a corporation organized under the Canada Business Corporations Act (“Rio Tinto”) (such stock and asset purchase, the “Alcan North America
Acquisition”), and (iii) all of the Equity Interests of certain direct and indirect subsidiaries of Alcan Asia Limited, a company limited by shares organized under the laws of Hong Kong and (b) assume certain liabilities of Rio
Tinto; 
 WHEREAS, the Borrowers have requested that the Administrative Agent and the Lenders agree to amend the Credit
Agreement to provide for certain amendments, including (a) an increase in the Revolving Commitments and (b) an extension of the Maturity Date. 
 NOW, THEREFORE, in consideration of the premises set forth above, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and without waiving any existing
or future rights or remedies which the Administrative Agent and the Lenders may have against the Borrowers or the other Loan Parties, the Administrative Agent and the Lenders party hereto are willing to agree to amend certain provisions of the
Credit Agreement on the terms and subject to the conditions expressly set forth herein. 

 1. Amendments to the Credit Agreement on the First Amendment Effective Date. Subject
to the satisfaction of the conditions precedent set forth in Section 3 below, the Borrowers, the Lenders party hereto, the Issuing Banks, the Swingline Lenders, and the Administrative Agent each agree that the Credit Agreement shall be
and hereby is amended as of the First Amendment Effective Date as follows: 
 (a) Section 1.01 of the Credit Agreement is
hereby amended as follows: 
 (i) The definition of “Cash Management Period” is hereby amended
by deleting each reference to “$50,000,000” contained therein and inserting “$75,000,000” in lieu thereof. 
 (ii) The definition of “Covenant Trigger Period” is hereby amended by deleting each reference to “$40,000,000” contained therein and inserting “$60,000,000” in lieu
thereof. 
 (iii) The definition of “Eligible Accounts” is hereby amended by deleting the
following text contained in clause (e) thereof: “(i) such Loan Party (A) with respect to an Account of a U.S. Loan Party, exceeds 15% of the aggregate amount of Eligible Accounts of all U.S. Loan Parties or (B) with respect to an
Account of a Canadian Loan Party, exceeds 15% of the aggregate amount of Eligible Accounts of all Canadian Loan Parties or (ii)”. 
 (iv) The definition of “Maturity Date” is hereby amended and restated in its entirety as follows: 
 “Maturity Date” means July 21, 2017, or any earlier date on which the Commitments are reduced to zero or otherwise terminated pursuant to the terms hereof; provided,
however, that (i) the Maturity Date shall automatically become August 16, 2013 unless (x) the Convertible Senior Notes are refinanced with Indebtedness that matures (excluding any maturity as the result of an optional
redemption by the issuer) or is mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, or is redeemable at the option of the holder thereof, in whole or in part, not earlier than the date that is 6 months after July 21,
2017, or (y) the Loan Parties have sufficient Liquidity such that, after giving pro forma effect to the repayment of the Convertible Senior Notes, Availability is at least $100,000,000 and the Fixed Charge Coverage Ratio is not less than 1.15
to 1.00 for the most recently ended quarter for which financial statements have been delivered to Administrative Agent in accordance with this Agreement, recalculated as if such repayment had been made on the last day of such quarter;
provided, further, that the Maturity Date shall automatically become December 31, 2014 unless (x) the Floating Rate Senior Unsecured Notes are refinanced with Indebtedness that matures (excluding any maturity as the result of
an optional redemption by the issuer) or is mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, or is redeemable at the option of the holder thereof, in whole or in part, not earlier than the date that is 6 months after
July 21, 2017, or (y) the Loan Parties have sufficient Liquidity such that, after giving pro forma effect to the repayment of the Floating Rate Senior Unsecured Notes, Availability is at least $100,000,000 and the Fixed Charge Coverage
Ratio is not less than 1.15 to 1.00 for the most recently ended quarter for which financial statements have been delivered to Administrative Agent in accordance with this Agreement, recalculated as if such repayment had been made on the last day of
such quarter; provided, further, that the Maturity Date shall automatically become December 31, 2016 unless (x) the Fixed Rate Senior Unsecured Notes are refinanced with Indebtedness that matures (excluding any maturity as
the result of an optional redemption by the issuer) or is mandatorily 

  
 2 

 
redeemable, pursuant to a sinking fund obligation or otherwise, or is redeemable at the option of the holder thereof, in whole or in part, not earlier than the date that is 6 months after
July 21, 2017, or (y) the Loan Parties have sufficient Liquidity such that, after giving pro forma effect to the repayment of the Fixed Rate Senior Unsecured Notes, Availability is at least $100,000,000 and the Fixed Charge Coverage Ratio
is not less than 1.15 to 1.00 for the most recently ended quarter for which financial statements have been delivered to Administrative Agent in accordance with this Agreement, recalculated as if such repayment had been made on the last day of such
quarter. 
 (v) The definition of “Monthly Reporting Period” is hereby amended by: 

(1) deleting each reference to “$300,000,000” contained therein and inserting “$450,000,000” in lieu
thereof; and 
 (2) deleting each reference to “$100,000,000” contained therein and inserting
“$150,000,000” in lieu thereof. 
 (vi) The definition of “Multicurrency Commitment”
is hereby amended by deleting the last sentence thereof and inserting the following sentence in lieu thereof: “The Multicurrency Commitment is in the aggregate amount of $50,000,000 as of the First Amendment Effective Date.” 

(vii) The definition of “Specified Conditions” is hereby amended by: 

(1) deleting each reference to “$100,000,000” contained therein and inserting “$150,000,000” in lieu
thereof; and 
 (2) deleting each reference to “$65,000,000” contained therein and inserting
“$97,500,000” in lieu thereof. 
 (viii) The definition of “U.S. Commitment” is
hereby amended by deleting the last sentence thereof and inserting the following sentence in lieu thereof: “The U.S. Commitment is in the aggregate amount of $550,000,000 as of the First Amendment Effective Date.” 

(ix) The definition of “Weekly Reporting Period” is hereby amended by deleting each reference to
“$50,000,000” contained therein and inserting “$75,000,000” in lieu thereof. 
 (x) The
following new definitions are hereby added to Section 1.01 of the Credit Agreement in proper alphabetical order: 
 “First Amendment” means that certain Amendment No. 1 to Credit Agreement, amending this Agreement. 

“First Amendment Effective Date” has the meaning specified in the First Amendment. 

(b) Section 2.05(a) of the Credit Agreement is hereby amended by deleting the reference to “$20,000,000” contained
therein and inserting “$30,000,000” in lieu thereof. 

  
 3 

 (c) Section 2.05(b) of the Credit Agreement is hereby amended by deleting the
reference to “$5,000,000” contained therein and inserting “$7,500,000” in lieu thereof. 
 (d)
Section 2.06(b) of the Credit Agreement is hereby amended by: 
 (i) deleting the reference to
“$100,000,000” contained therein and inserting “$150,000,000” in lieu thereof; 
 (ii)
deleting the reference to “$90,000,000” contained therein and inserting “$125,000,000” in lieu thereof; and 
 (iii) deleting the reference to “$10,000,000” contained therein and inserting “$25,000,000” in lieu thereof. 
 (e) Section 2.09(e) of the Credit Agreement is hereby amended by: 
 (i) deleting the comma immediately before the text “(v)”; 
 (ii) inserting the text “and” immediately before the text “(v)”; 
 (iii) deleting the text “and (vi) each such increase shall increase the U.S. Commitment and the Multicurrency Commitment ratably in accordance with the aggregate amount of such Revolving
Commitments at such time”. 
 (f) Section 2.09(f) of the Credit Agreement is hereby amended by deleting the reference
to “$500,000,000” contained therein and inserting “$800,000,000” in lieu thereof. 
 (g) Section 5.11
of the Credit Agreement is hereby amended by deleting the reference to “$50,000,000” contained therein and inserting “$75,000,000” in lieu thereof. 
 (h) Section 5.12 of the Credit Agreement is hereby amended by deleting the reference to “$50,000,000” contained therein and inserting “$75,000,000” in lieu thereof. 

(i) Section 9.02(b)(ii)(A) of the Credit Agreement is hereby amended by deleting the text “such” immediately after the
text “without the written consent of” and inserting “each” in lieu thereof. 
 (j) The Revolving Commitment
Schedule is hereby amended and restated as set forth on Exhibit A-1 hereto. 
 2. Amendments to the Credit Agreement on the
Alcan Amendment Effective Date. Subject to the satisfaction of the conditions precedent set forth in Section 4 below, the Borrowers, the Lenders party hereto, the Issuing Banks, the Swingline Lenders, and the Administrative Agent
each agree that the Credit Agreement shall be further amended as of the Alcan Amendment Effective Date as follows: 
 (a)
Section 1.01 of the Credit Agreement shall be amended as follows: 
 (i) The definition of
“Canadian PP&E Component” shall be amended and restated in its entirely as follows: 

“Canadian PP&E Component” means, at the time of any determination, an amount equal to the lesser of:

  
 4 

 (a) the Alcan Canadian PP&E Component plus the General
Cable Canadian PP&E Component, or 
 (b) $125,000,000 minus the U.S. PP&E Component
minus Reserves established by the Administrative Agent.” 
 (ii) The definition of
“Cash Management Period” shall be amended by deleting each reference to “$75,000,000” contained therein and inserting “$87,500,000” in lieu thereof. 

(iii) The definition of “Change in Control” shall be amended by inserting the following sentence at the end of
such definition: 
 “Notwithstanding the foregoing, a Permitted Canadian Borrower Amalgamation shall not
constitute a Change in Control.” 
 (iv) The definition of “Covenant Trigger Period”
shall be amended by deleting each reference to “$60,000,000” contained therein and inserting “$70,000,000” in lieu thereof. 
 (v) The definition of “Monthly Reporting Period” shall be amended by: 
 (1) deleting each reference to “$450,000,000” contained therein and inserting “$525,000,000” in lieu thereof; and 

(2) deleting each reference to “$150,000,000” contained therein and inserting “$175,000,000” in lieu
thereof. 
 (vi) The definition of “Multicurrency Commitment” shall be amended by deleting the
last sentence thereof and inserting the following sentence in lieu thereof: “The Multicurrency Commitment is in the aggregate amount of $70,000,000 as of the Alcan Amendment Effective Date.” 

(vii) The definition of “PP&E Amortization Factor” shall be deleted in its entirety. 

(viii) The definition of “Specified Conditions” shall be amended by: 

(1) deleting each reference to “$150,000,000” contained therein and inserting “$175,000,000” in lieu
thereof; and 
 (2) deleting each reference to “$97,500,000” contained therein and inserting
“$113,750,000” in lieu thereof. 
 (ix) The definition of “U.S. Commitment” shall be
amended by deleting the last sentence thereof and inserting the following sentence in lieu thereof: “The U.S. Commitment is in the aggregate amount of $630,000,000 as of the Alcan Amendment Effective Date.” 

  
 5 

 (x) The definition of “U.S. PP&E Component” shall be
amended and restated in its entirely as follows: 
 “U.S. PP&E Component” means, at the time
of any determination, the lesser of (a) the Alcan U.S. PP&E Component plus the General Cable U.S. PP&E Component or (b) $125,000,000.” 

(xi) The definition of “Weekly Reporting Period” shall be amended by deleting each reference to
“$75,000,000” contained therein and inserting “$87,500,000” in lieu thereof. 
 (xii) The
following new definitions shall be added to Section 1.01 of the Credit Agreement in proper alphabetical order: 
 “Alcan Acquisition” means (a) the acquisition by Holdings, through one or more of its Subsidiaries, of (i) all of the Equity Interests of certain direct and indirect
subsidiaries organized, established or incorporated, as the case may be, under the laws of certain States of the United States and Mexico, as applicable, of Rio Tinto plc, a company incorporated in England with registered number 719885,
(ii) certain assets of Rio Tinto Alcan Inc., a corporation organized under the Canada Business Corporations Act (“Rio Tinto”), and (iii) all of the Equity Interests of certain direct and indirect subsidiaries of Alcan Asia
Limited, a company limited by shares organized under the laws of Hong Kong and (b) the assumption by Holdings, through one or more of its Subsidiaries, of certain liabilities of Rio Tinto. 

“Alcan Amendment Effective Date” has the meaning specified for such term in the First Amendment.

 “Alcan Canadian PP&E Component” means an amount equal to the Alcan PP&E Amortization
Factor multiplied by 85% of the Net Orderly Liquidation Value of the Canadian Loan Parties’ Alcan Eligible Equipment minus Reserves established by the Administrative Agent. 

“Alcan Eligible Equipment” means the Equipment reflected in a Report delivered to the Administrative
Agent in connection with the Alcan Acquisition and satisfying the criteria set forth in the definition of “Eligible Equipment”. 
 “Alcan Eligible Real Property” means the real estate reflected in a Report delivered to the Administrative Agent in connection with the Alcan Acquisition and satisfying the criteria set
forth in the definition of “Eligible Real Property”. 
 “Alcan PP&E Amortization
Factor” means 1 minus a fraction, the numerator of which is the number of full calendar quarters elapsed as of any date of determination (including any calendar quarter ending on the date of determination) since March 31, 2013, (but in
no event more than 28) and the denominator of which is 28. 
 “Alcan U.S. PP&E Component”
means an amount equal to the Alcan PP&E Amortization Factor multiplied by (a) 75% of the fair market value of the U.S. Loan Parties’ Alcan Eligible Real Property plus (b) 85% of the Net Orderly
Liquidation Value of the U.S. Loan Parties’ Alcan Eligible Equipment minus (c) Reserves established by the Administrative Agent. 

  
 6 

 “General Cable Canadian PP&E Component” means an amount
equal to the General Cable PP&E Amortization Factor multiplied by (a) 85% of the Net Orderly Liquidation Value of the Canadian Loan Parties’ Eligible Equipment (excluding the Canadian Loan Parties’ Alcan
Eligible Equipment) minus (b) Reserves established by the Administrative Agent. 

“General Cable PP&E Amortization Factor” means 1 minus a fraction, the numerator of which is the
number of full calendar quarters elapsed as of any date of determination (including any calendar quarter ending on the date of determination) since September 30, 2011, (but in no event more than 28) and the denominator of which is 28.

 “General Cable U.S. PP&E Component” means an amount equal to the General Cable PP&E
Amortization Factor multiplied by (a) 75% of the fair market value of the U.S. Loan Parties’ Eligible Real Property (excluding the U.S. Loan Parties’ Alcan Eligible Real Property) plus (b) 85%
of the Net Orderly Liquidation Value of the U.S. Loan Parties’ Eligible Equipment (excluding the U.S. Loan Parties’ Alcan Eligible Equipment) minus (c) Reserves established by the Administrative Agent. 

“Permitted Canadian Borrower Amalgamation” shall mean the amalgamation of the Canadian Borrower and
General Cable Canada, Ltd., a corporation organized under the laws of Ontario, on a single occasion on or before the date that is one hundred twenty (120) days (or such longer period as the Administrative Agent shall agree in its reasonable
discretion) after the Alcan Amendment Effective Date; provided that (i) no Default or Event of Default has occurred and is continuing or would result therefrom and the representations and warranties contained in Section 3 and
each of the other Loan Documents are true and correct in all material respects on and as of the date of the amalgamation as though made on and as such date (it being understood and agreed that any representation or warranty which by its terms is
made as of a specified date shall be required to be true and correct in all material respects only as of such specified date), and that any representation or warranty which is subject to any materiality qualifier shall be required to be true and
correct in all respects; (ii) the person resulting from such amalgamation shall (A) be a corporation amalgamated under the Canada Business Corporations Act (such resulting person, the “Successor Canadian Borrower”) and
(B) the Successor Canadian Borrower shall expressly confirm its obligations as the Canadian Borrower under this Agreement and the other Loan Documents to which the Canadian Borrower is a party pursuant to a confirmation in form and substance
reasonably satisfactory to the Administrative Agent; (iii) a Loan Party shall directly own 100% of the Equity Interests of the Successor Canadian Borrower; (iv) immediately upon consummation of such amalgamation, Holdings shall pledge and
deliver to the Administrative Agent the certificates, if any, representing 65% of the Equity Interests of the Successor Canadian Borrower, together with undated stock powers or other appropriate instruments of transfer executed and delivered in
blank by a duly authorized officer of Holdings; (v) immediately after giving effect to any such amalgamation, the Fixed Charge Coverage Ratio is not less than the Fixed Charge Coverage Ratio immediately prior to such amalgamation by more than
..20%, such compliance to be determined on the basis of the financial information most recently delivered to the Administrative Agent pursuant to Section 5.01(a) or (b) as though such amalgamation had been consummated as of
the first day of the fiscal period covered thereby and evidenced by a certificate from the chief financial officer of the Borrower Representative demonstrating such compliance calculation in reasonable detail; (vi) the Successor Canadian
Borrower shall have no Indebtedness after giving effect to the Permitted 

  
 7 

 
Canadian Borrower Amalgamation other than Indebtedness of the Canadian Borrower in existence prior to the date of the Permitted Canadian Borrower Amalgamation and Indebtedness otherwise permitted
by this Agreement; (vii) each other Loan Guarantor shall have by a confirmation in form and substance reasonably satisfactory to the Administrative Agent, confirmed that its guarantee of the Guaranteed Obligations (including its Guarantee)
shall apply to the Successor Canadian Borrower’s obligations under this Agreement; (viii) each other Loan Party shall have by confirmations and any required supplements to the applicable Collateral Documents reasonably requested by the
Administrative Agent, in each case, in form and substance reasonably satisfactory to the Administrative Agent, confirmed that its obligations thereunder shall apply to the Successor Canadian Borrower’s obligations under this Agreement; and
(ix) the Successor Canadian Borrower shall have delivered opinions of counsel and related officers’ certificates reasonably requested by the Administrative Agent (including with respect to the execution and delivery and enforceability of
the documents referred to above and the compliance of such amalgamation with the provisions hereof, and with respect to the Liens granted pursuant to the Collateral Documents), and all such opinions of counsel shall be satisfactory to the
Administrative Agent; and provided, further, that (x) if the foregoing are satisfied, the Successor Canadian Borrower will be substituted for and assume all obligations of the Canadian Borrower under this Agreement and each of the
other Loan Documents and all references hereunder and under the other Loan Documents to the Canadian Borrower shall be references to the Successor Canadian Borrower and (y) notwithstanding any provision of Section 9.02, the
Administrative Agent is hereby authorized by the Lenders to make any amendments to the Loan Documents that are necessary or desirable to reflect such changes in the parties to the applicable Loan Documents. 

“Successor Canadian Borrower” shall have the meaning assigned to such term in the definition of
“Permitted Canadian Borrower Amalgamation”. 
 (b) Section 1.03(a) of the Credit Agreement shall be amended by
inserting the following sentence at the end thereof: 
 “From and after the effectiveness of the Permitted
Canadian Borrower Amalgamation, all references to the Canadian Borrower in any Loan Document shall refer to the Successor Canadian Borrower.” 
 (c) Section 2.05(a) of the Credit Agreement shall be amended by deleting the reference to “$30,000,000” contained therein and inserting “$35,000,000” in lieu thereof. 

(d) Section 2.05(b) of the Credit Agreement shall be amended by deleting the reference to “$7,500,000” contained therein
and inserting “$8,750,000 in lieu thereof” 
 (e) Section 2.06(b) of the Credit Agreement shall be amended by:

 (i) deleting the reference to “$150,000,000” contained therein and inserting
“$175,000,000” in lieu thereof; 
 (ii) deleting the reference to “$125,000,000” contained
therein and inserting “$142,500,000” in lieu thereof; and 

  
 8 

 (iii) deleting the reference to “$25,000,000” contained therein
and inserting “$32,500,000” in lieu thereof. 
 (f) Section 5.11 of the Credit Agreement shall be amended by
deleting the reference to “$75,000,000” contained therein and inserting “$87,500,000” in lieu thereof. 

(g) Section 5.12 of the Credit Agreement shall be amended by deleting the reference to “$75,000,000” contained therein
and inserting “$87,500,000” in lieu thereof. 
 (h) Section 6.03(a) of the Credit Agreement shall be amended by:

 (i) deleting the reference to “ and” contained in clause (vi) and inserting a comma in lieu
thereof; 
 (ii) inserting the word “and” at the end of clause (vii) thereof; 

(iii) inserting a new clause (viii) at the end thereof as follows: 

“(viii) the Canadian Borrower may consummate the Permitted Canadian Borrower Amalgamation”. 

(i) Section 6.11 of the Credit Agreement shall be amended by inserting the text “or a Permitted Canadian Borrower
Amalgamation” immediately after the text “Permitted Reorganization”. 
 (j) Section 9.02 of the Credit
Agreement shall be amended by inserting the following clause (e) at the end thereof as follows: 
 “(e)
Notwithstanding the foregoing, the Administrative Agent and the Borrower Representative (without the consent of any Lenders) may amend or amend and restate this Agreement and the other Loan Documents if necessary or advisable in connection with or
to effectuate the Permitted Canadian Borrower Amalgamation.” 
 (k) The Revolving Commitment Schedule shall be amended and
restated as set forth on Exhibit A-2 hereto. 
 3. Conditions to the First Amendment Effective Date. The amendments to
the Credit Agreement set forth in Section 1 above shall become effective as of the date hereof (the “First Amendment Effective Date”) upon: 
 (a) the Administrative Agent’s receipt of counterparts of this Amendment executed by each Borrower, each other Loan Party, the Administrative Agent, each Issuing Bank, each Swingline Lender and each
Lender; 
 (b) the Administrative Agent shall have received a certificate signed by a duly authorized officer of each Borrower
to the effect that, before and after giving effect to this Amendment on the First Amendment Effective Date: (i) the representations and warranties contained in Article III of the Credit Agreement and each of the other Loan Documents are true
and correct in all material respects on and as of the date of such certificate as though made on and as of each such date (it being understood and agreed that any representation or warranty which by its terms is made as of a specified date shall be
required to be true and correct in all material respects only as of such specified date), and that any representation or warranty which is subject to any materiality qualifier shall be required to be true and correct in all respects; (ii) no
Default or Event of Default has occurred and is continuing or would result 

  
 9 

 
after giving effect to this Amendment and (iii) neither the increase in Commitments, nor the funding thereof, nor the existence of the Liens securing such increase will violate the terms of
the Convertible Senior Note Documents, the Senior Unsecured Note Documents, the Subordinated Convertible Note Documents or the 2007 Senior Unsecured Convertible Note Documents, or the documentation of any other Indebtedness of any Loan Party, in
each case as in effect on the date hereof; 
 (c) the Borrowers shall have delivered all customary agreements, certificates,
opinions and other customary documents reasonably requested by the Administrative Agent; 
 (d) after giving effect to all
Borrowings to be made on the First Amendment Effective Date and the issuance of any Letters of Credit on the First Amendment Effective Date and payment of all fees, expenses and other amounts due hereunder or pursuant to any Loan Document, and with
all of the Loan Parties’ indebtedness, liabilities, and obligations current, Availability shall not be less than $150,000,000; and 
 (e) the Borrowers shall have paid to JPMorgan Chase (i) for the benefit of the Lenders (including JPMorgan Chase in its capacity as a Lender), the Extension Fee and (ii) such other fees or other
amounts as may be then payable pursuant to any Loan Document. 
 4. Conditions to the Alcan Amendment Effective Date.
This amendments to the Credit Agreement set forth in Section 2 above shall become effective as of the date on which the following conditions are satisfied (the “Alcan Amendment Effective Date”): 

(a) the First Amendment Effective Date has occurred; 
 (b) the Administrative Agent shall have received a certificate signed by a duly authorized officer of each Borrower to the effect that, before and after giving effect to this Amendment on the Alcan
Amendment Effective Date: (i) the representations and warranties contained in Article III of the Credit Agreement and each of the other Loan Documents are true and correct in all material respects on and as of the date of such certificate as
though made on and as of each such date (it being understood and agreed that any representation or warranty which by its terms is made as of a specified date shall be required to be true and correct in all material respects only as of such specified
date), and that any representation or warranty which is subject to any materiality qualifier shall be required to be true and correct in all respects; (ii) no Default or Event of Default has occurred and is continuing or would result after
giving effect to the Alcan Acquisition and (iii) neither the increase in Commitments, nor the funding thereof, nor the existence of the Liens securing such increase will violate the terms of the Convertible Senior Note Documents, the Senior
Unsecured Note Documents, the Subordinated Convertible Note Documents or the 2007 Senior Unsecured Convertible Note Documents, or the documentation of any other Indebtedness of any Loan Party, in each case as in effect on the date hereof;

 (c) the Borrowers shall have delivered all customary agreements, certificates, opinions and other customary documents
(including an updated perfection certificate) reasonably requested by the Administrative Agent; 
 (d) on or before the date
that is one hundred twenty (120) days after the First Amendment Effective Date, the Alcan North America Acquisition shall have been consummated, pursuant to acquisition documentation in form and substance satisfactory to the Administrative
Agent; 
 (e) after giving effect to all Borrowings to be made on the Alcan Amendment Effective Date and the issuance of any
Letters of Credit on the Alcan Amendment Effective Date and payment of all fees, expenses and other amounts due hereunder or pursuant to any Loan Document, and with all of the Loan Parties’ indebtedness, liabilities, and obligations current,
Availability shall not be less than $175,000,000; and 

  
 10 

 (f) the Borrowers shall have paid to JPMorgan Chase such fees or other amounts as may be
then payable pursuant to any Loan Document. 
 5. Covenants. With respect to any new Subsidiary (other than Immaterial
Subsidiaries) or assets acquired pursuant to the Alcan Acquisition, each Loan Party shall comply with the terms of Section 5.14 of the Credit Agreement and each other requirement of the Loan Documents regarding new Subsidiaries or
newly-acquired assets, in each case within the time period set forth therein, it being understood and agreed that, prior to inclusion of any assets acquired in connection with the Alcan Acquisition in the determination of the Borrowing Base,
(i) the owner of such assets shall have been joined as a Loan Party and shall have complied with all applicable requirements, whether set forth in Section 5.14 of the Credit Agreement or otherwise set forth in the Loan Documents, in
connection therewith and (ii) due diligence (including, without limitation, field exams and appraisals) in respect of such acquired assets satisfactory to the Administrative Agent, in its Permitted Discretion, shall be completed. 

6. Representations and Warranties of the Borrowers. Each Borrower represents and warrants to each Lender and the Administrative
Agent as of the date hereof and as of the Alcan Amendment Effective Date as follows: 
 (a) Each Borrower has the legal power
and authority to execute and deliver this Amendment and the officers of each Borrower executing this Amendment have been duly authorized to execute and deliver the same and bind such Borrower with respect to the provisions hereof. 

(b) This Amendment has been duly executed and delivered by each Loan Party that is a party hereto. 

(c) This Amendment and the Credit Agreement as modified hereby (the “Amended Agreement”) each constitutes the legal,
valid and binding obligations of each Borrower and each other Loan Party, enforceable against it in accordance with their terms (except as enforceability may be limited by bankruptcy, insolvency or similar laws affecting the enforcement of
creditors’ rights generally). 
 (d) The execution and delivery by each Loan Party of this Amendment, the performance by
each Loan Party of its obligations under the Amended Agreement and under the other Loan Documents to which they are parties and the consummation of the transactions contemplated by the Amended Agreement and the other Loan Documents: (i) do not
require any consent or approval of, registration or filing with, notice to or any other action by or in respect of, any Governmental Authority or any other Person, except (A) those consents, approvals, registrations, filings, notices and other
actions as have been obtained or made and are in full force and effect and (B) for filings necessary to perfect Liens created pursuant to the Loan Documents, (ii) will not violate any material Requirement of Law applicable to any Loan
Party, (iii) will not violate or result in a default under any material indenture, agreement or other instrument binding upon any Loan Party or any of its Subsidiaries or the assets of any Loan Party or any of its Subsidiaries, or give rise to
a right thereunder to require any payment to be made by any Loan Party or any of its Subsidiaries, (iv) will not contravene the terms of any certificates of incorporation, by-laws or other organizational or governing documents of any Loan
Party, and (v) will not result, or require, the creation or imposition of any Lien on any asset of any Loan Party, except Liens created pursuant to the Loan Documents and Permitted Liens. 

  
 11 

 (e) Each Borrower and each other Loan Party hereby reaffirms all covenants, representations
and warranties made by it in the Credit Agreement and the other Loan Documents and agrees and confirms that all such representations and warranties are true and correct in all material respects as of the date of this Amendment (it being understood
and agreed that any representation or warranty which by its terms is made as of a specified date shall be required to be true and correct in all material respects only as of such specified date), and that any representation or warranty which is
subject to any materiality qualifier is true and correct in all respects. 
 (f) Each Borrower has caused to be conducted a
thorough review of the terms of this Amendment, the Credit Agreement and the other Loan Documents and each Borrower’s and its Subsidiaries’ operations since the Effective Date and, as of the date hereof and as of the Alcan Amendment
Effective Date and after giving effect to the terms hereof, no Default or Event of Default has occurred and is continuing. 
 7.
Reference to and Effect on the Credit Agreement. 
 (a) On and after the First Amendment Effective Date, each reference
in the Credit Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import shall mean and be a reference to the Credit Agreement as modified by Section 1 above.

 (b) On and after the Alcan Amendment Effective Date, each reference in the Credit Agreement to “this Agreement,”
“hereunder,” “hereof,” “herein” or words of like import shall mean and be a reference to the Credit Agreement as modified by Section 1 above, and as further modified by Section 2 above.

 (c) Except as specifically waived or modified above, the Credit Agreement and all other documents, instruments and agreements
executed and/or delivered in connection therewith, shall remain in full force and effect, and are hereby ratified and confirmed. 
 (d) The execution, delivery and effectiveness of this Amendment shall not, unless and except as expressly provided herein, operate as a waiver of any right, power or remedy of the Administrative Agent or
the Lenders, nor constitute a waiver of any provision of the Credit Agreement or any other documents, instruments and agreements executed and/or delivered in connection therewith. 

8. Costs and Expenses; Extension Fee; Commitment Fee. 
 (a) Each Borrower agrees to pay all reasonable out-of-pocket expenses incurred by the Administrative Agent and its Affiliates, including the reasonable fees, charges and disbursements of counsel for the
Administrative Agent, in connection with the syndication and distribution (including, without limitation, via the internet or through a service such as Intralinks) of the credit facilities provided for herein and in the Credit Agreement as amended
hereby, and in connection with the preparation, arrangement, execution and enforcement of this Amendment and all other instruments, agreements and other documents executed in connection herewith. 

(b) The U.S. Borrower agrees to pay, on the First Amendment Effective Date, to JPMorgan Chase for the benefit of the Lenders (including
JPMorgan Chase in its capacity as a Lender) having Revolving Commitments prior to the First Amendment Effective Date, an extension fee (the “Extension Fee”) equal to 0.125% of the aggregate principal amount of the Revolving
Commitments prior to the First Amendment Effective Date, based on Revolving Commitment level, and payable based on the Revolving Commitment Schedule in effect prior to the First Amendment Effective Date. 

(c) From the 60th day after the First Amendment Effective Date until the earlier of the Alcan Acquisition Effective Date and the
120th day after the First Amendment Effective Date, solely
for the purposes of calculating the commitment fee set forth under Section 2.12(a) of the Credit 

  
 12 

 
Agreement (including both the average daily unused portion of the Revolving Commitment and the average daily amount of each Lender’s Applicable Percentage of the Available Revolving
Commitment), the Revolving Commitment Schedule shall be deemed to be as set forth on Exhibit A-2 hereto. 
 9. Governing
Law. ANY DISPUTE BETWEEN ANY LOAN PARTY AND ANY OTHER PARTY HERETO ARISING OUT OF, CONNECTED WITH, RELATED TO, OR INCIDENTAL TO THE RELATIONSHIP ESTABLISHED BETWEEN THEM IN CONNECTION WITH, THIS AMENDMENT, THE CREDIT AGREEMENT OR ANY OF THE
OTHER LOAN DOCUMENTS, AND WHETHER ARISING IN CONTRACT, TORT, EQUITY, OR OTHERWISE, SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS (AND NOT THE LAW OF CONFLICTS) OF THE STATE OF NEW YORK, BUT GIVING EFFECT TO FEDERAL LAWS
APPLICABLE TO NATIONAL BANKS. 
 10. Headings. Section headings in this Amendment are included herein for convenience of
reference only and shall not constitute a part of this Amendment for any other purpose. 
 11. Counterparts. This
Amendment may be executed in any number of counterparts, all of which taken together shall constitute one agreement, and any of the parties hereto may execute this Amendment by signing any such counterpart. A facsimile signature page hereto sent to
the Administrative Agent or the Administrative Agent’s counsel shall be effective as a counterpart signature provided each party executing such a facsimile counterpart agrees, if requested, to deliver originals thereof to the Administrative
Agent. 
 12. No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of
this Amendment, the Credit Agreement and the other Loan Documents. In the event an ambiguity or question of intent or interpretation arises, this Amendment, the Credit Agreement and the other Loan Documents shall be construed as if drafted jointly
by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Amendment, the Credit Agreement or any of the other Loan Documents. 

13. Amendment Constitutes Loan Document. This Amendment shall constitute a “Loan Document” for purposes of the Credit
Agreement and the other Loan Documents. 
 14. Reaffirmation of Liens and Guaranties. 

(a) Acknowledgment. Each Loan Guarantor hereby (i) acknowledges receipt of a copy this Amendment and (ii) consents to
the amendment of the Credit Agreement effected hereby. Each Loan Guarantor acknowledges and agrees that any of the Loan Documents to which it is a party or otherwise bound shall continue in full force and effect and that all of its obligations
thereunder shall be valid and enforceable and shall not be impaired or limited by the execution or effectiveness of the Amendment. 
 (b) Reaffirmation of Liens. Each of the Loan Parties hereby ratifies, confirms and reaffirms the grant by it of the Liens and security interests in Collateral in which it has rights pursuant to the
terms of, and its obligations and agreements under, the Collateral Documents, confirms that this Amendment does not constitute a novation, payment and reborrowing or termination of the Secured Obligations under the Credit Agreement and the other
Loan Documents as in effect prior to the First Amendment Date and confirms that all such Collateral will continue to secure the payment and performance of all Secured Obligations purported to be secured thereby (including any amount payable under
the Credit Agreement as amended by this Amendment). 

  
 13 

 (c) Reaffirmation of Guaranties. Without limiting or qualifying the foregoing, each
of the Loan Guarantors hereby ratifies, confirms and reaffirms its obligations and agreements under Article X of the Credit Agreement. 
 [The remainder of this page is intentionally blank] 

  
 14 

 IN WITNESS WHEREOF, this Amendment has been duly executed as of the day and year first above
written. 
  

			
	GENERAL CABLE INDUSTRIES, INC.,
	as the U.S. Borrower
		
	By	 	/s/ Brian J. Robinson
		 	Name:  Brian J. Robinson
		 	 Title:    Executive Vice President, Chief Financial Officer and Treasurer

	
	GENERAL CABLE COMPANY,as the Canadian Borrower
		
	By	 	/s/ Brian J. Robinson
		 	Name:  Brian J. Robinson
		 	 Title:    Executive Vice President, Chief Financial Officer and Treasurer

	
	OTHER LOAN PARTIES
	
	GENERAL CABLE CORPORATION
	GK TECHNOLOGIES, INCORPORATED
	 GENERAL CABLE TECHNOLOGIES
     CORPORATION

	DIVERSIFIED CONTRACTORS, INC.
	GC GLOBAL HOLDINGS, INC.
	GENCA CORPORATION
	 MARATHON MANUFACTURING HOLDINGS,
     INC.

	MLTC COMPANY
	MARATHON STEEL COMPANY
	GENERAL CABLE INDUSTRIES, LLC
	GENERAL CABLE OVERSEAS HOLDINGS, LLC
	GENERAL CABLE CANADA LTD.
		
	By	 	/s/ Brian J. Robinson
		 	Name:  Brian J. Robinson
		 	 Title:    Executive Vice President, Chief Financial Officer and Treasurer

  
 [Signature
Page to the First Amendment] 

 
			
	PHELPS DODGE INTERNATIONAL CORPORATION
	PHELPS DODGE ENFIELD CORPORATION
	PD WIRE & CABLE SALES CORPORATION
	PHELPS DODGE AFRICA CABLE CORPORATION
	PHELPS DODGE NATIONAL CABLES CORPORATION
		
	By	 	/s/ Brian J. Robinson
		 	Name:  Brian J. Robinson
		 	 Title:    Executive Vice President, Chief Financial Officer and Treasurer

		
	By	 	/s/ Robert J. Siverd
		 	Name:  Robert J. Siverd
		 	 Title:    Executive Vice President and Secretary

  
 [Signature
Page to the First Amendment] 

 
			
	JPMORGAN CHASE BANK, N.A., individually and as Administrative Agent, U.S. Issuing Bank and U.S. Swingline Lender
		
	By	 	/s/ Katherine Cliffel
		 	Name:  Katherine C. Cliffel
		 	 Title:    Vice President & Auth. Signer

	
	JPMORGAN CHASE BANK, N.A., TORONTO BRANCH, as Canadian Issuing Bank and Multicurrency Swingline Lender
		
	By	 	/s/ Agostino A. Marchetti
		 	Name:  Agostino A. Marchetti
		 	 Title:    SVP

  
 [Signature
Page to the First Amendment] 

			
	CREDIT AGRICOLE CORPORATE
	AND INVESTMENT BANK
		
	By	 	/s/ Blake Wright
		 	  

		 	 Name:  Blake Wright

		 	 Title:    Managing Director

		
	By	 	/s/ Corey Billups
		 	  

		 	 Name:  Corey Billups

		 	 Title:    Managing Director

	
	WELLS FARGO BANK, N.A.
		
	By	 	/s/ Kevin S. Fong
		 	  

		 	 Name:  Kevin S. Fong

		 	 Title:    Vice President

	
	WELLS FARGO CAPITAL FINANCE CORPORATION CANADA
		
	By	 	/s/ Domenic Cosentino
		 	  

		 	 Name:  Domenic Cosentino

		 	 Title:    Vice President Wells Fargo Capital Finance Corporation Canada and Authorized
Signatory

	
	DEUTSCHE BANK AG NEW YORK BRANCH
		
	By	 	/s/ Erin Morrissey
		 	  

		 	 Name:  Erin Morrissey

		 	 Title:    Director

		
	By	 	/s/ Marguerite Sutton
		 	  

		 	Name: Marguerite Sutton
		 	Title: Director
	
	DEUTSCHE BANK AG CANADA BRANCH
		
	By	 	/s/ Paul M. Jurist
		 	  

		 	 Name:  Paul M. Jurist

		 	 Title:    Managing Director and Principal Officer

		
	By	 	/s/ Marcellus Leung
		 	  

		 	 Name:  Marcellus Leung

		 	 Title:    Assistant Vice President

	
	KEYBANK NATIONAL ASSOCIATION
		
	By	 	/s/ Rufus S. Dowe III
		 	  

		 	 Name:  Rufus S. Dowe III

		 	 Title:    Vice President

  
 [Signature
Page to the First Amendment] 

			
	PNC BANK, NATIONAL ASSOCIATION
		
	By	 	/s/ C. Joseph Richardson
		 	  

		 	 Name:  C. Joseph Richardson

		 	 Title:    Senior Vice President

	
	PNC BANK CANADA BRANCH
		
	By	 	/s/ Caroline Stade
		 	  

		 	 Name:  Caroline Stade

		 	 Title:    Senior Vice President

		
	By	 	/s/ Bill Hines
		 	  

		 	 Name:  Bill Hines

		 	 Title:    Senior Vice President & Principal Officer

	
	BANK OF AMERICA, N.A.
		
	By	 	/s/ Brian Roman
		 	  

		 	 Name:  Brian Roman

		 	 Title:    Vice President

	
	BANK OF AMERICA, N.A.
	Acting Through its Canada Branch
		
	By	 	/s/ Medina Sales de Andrade
		 	  

		 	 Name:  Medina Sales de Andrade

		 	 Title:    Vice President

	
	BRANCH BANKING AND TRUST COMPANY,
	A North Carolina Banking Corporation
		
	By	 	/s/ Greg R. Branstetter
		 	  

		 	 Name:  Greg R. Branstetter

		 	 Title:    Senior Vice President

	
	THE HUNTINGTON NATIONAL BANK
	As a U.S. Revolving Lender
		
	By	 	/s/ Michael W. Kempel
		 	  

		 	 Name:  Michael W. Kempel

		 	 Title:    Senior Regional Director

	
	COMPASS BANK
	As a U.S. Revolving Lender
		
	By	 	/s/ Michael Sheff
		 	  

		 	 Name:  Michael Sheff

		 	 Title:    Senior Vice President

  
 [Signature
Page to the First Amendment] 

			
	STANDARD CHARTERED BANK
		
	By	 	/s/ James P. Hughes
		 	  

		 	 Name:  James P. Hughes

		 	 Title:    Director

		
	By	 	/s/ Robert K. Reddington
		 	  

		 	 Name:  Robert K. Reddington

		 	 Title:    Credit Documentation Manager

		 	Credit Documentation Unit, WB Legal Americas
	
	CAPITAL ONE LEVERAGE FINANCE CORP.
		
	By	 	/s/ J. Davisson
		 	  

		 	 Name:  J. Davisson

		 	 Title:    Senior Vice President

	
	FIFTH THIRD BANK
	Operating through its Canadian Branch
		
	By	 	/s/ Charles Miller
		 	  

		 	 Name:  Charles Miller

		 	 Title:    Vice President

	
	 FIFTH THIRD BANK,

An Ohio Banking Corp.

		
	By	 	/s/ P. Ann Daniel
		 	  

		 	 Name:  P. Ann Daniel

		 	 Title:    Officer

	
	HSBC BANK USA, N.A.
		
	By	 	/s/ Christopher S. Helmeci
		 	  

		 	 Name:  Christopher S. Helmeci

		 	 Title:    Sr. Relationship Manager

	
	HSBC BANK CANADA
		
	By	 	/s/ Tim Robbins
		 	  

		 	 Name:  Tim Robbins

		 	 Title:    Assistant Vice President

	
	US BANK NATIONAL ASSOCIATION
		
	By	 	/s/ Matthew Kasper
		 	  

		 	 Name:  Matthew Kasper

		 	 Title:    Vice President

  
 [Signature
Page to the First Amendment] 

			
	US BANK, N.A., CANADA BRANCH
	As Canadian Lender
		
	By	 	/s/ Joseph Rauhala
		 	  

		 	 Name:  Joseph Rauhala

		 	 Title:    Principal Officer

	
	RB INTERNATIONAL FINANCE (USA) LLC
		
	By	 	/s/ Christoph Hoedl
		 	  

		 	 Name:  Christoph Hoedl

		 	 Title:    First Vice President

		
	By	 	/s/ John A. Valiska
		 	  

		 	 Name:  John A. Valiska

		 	 Title:    First Vice President

  
 [Signature
Page to the First Amendment] 

 EXHIBIT A-1 
 REVOLVING COMMITMENT SCHEDULE 
  

									
	 Lender
	  	U.S. Commitment	 	  	Multicurrency Commitment	 
	 JPMorgan Chase Bank N.A.
	  	$	99,642,857.14	  	  	 	—  	  
	 JPMorgan Chase Bank, N.A., Toronto Branch
	  	 	—  	  	  	$	16,071,428.57	  
	 Credit Agricole Corporate and Investment Bank
	  	$	58,928,571.43	  	  	$	5,357,142.86	  
	 Wells Fargo Bank N.A.
	  	$	58,928,571.43	  	  	 	—  	  
	 Wells Fargo Capital Finance Corporation Canada
	  	 	—  	  	  	$	5,357,142.86	  
	 Deutsche Bank AG New York Branch
	  	$	35,357,142.86	  	  	 	—  	  
	 Deutsche Bank AG Canada Branch
	  	 	—  	  	  	$	3,214,285.71	  
	 KeyBank National Association
	  	$	35,357,142.86	  	  	$	3,214,285.71	  
	 PNC Bank, National Association
	  	$	35,357,142.86	  	  	 	—  	  
	 PNC Bank Canada Branch
	  	 	—  	  	  	$	3,214,285.71	  
	 Bank of America, N.A.
	  	$	27,500,000.00	  	  	 	—  	  
	 Bank of America, N.A. (acting through its Canada Branch)
	  	 	—  	  	  	$	2,500,000.00	  
	 Branch Banking & Trust Company
	  	$	27,500,000.00	  	  	$	2,500,000.00	  
	 The Huntington National Bank
	  	$	30,000,000.00	  	  	 	—  	  
	 Compass Bank
	  	$	25,714,285.71	  	  	 	—  	  
	 Standard Chartered Bank
	  	$	23,571,428.57	  	  	$	2,142,857.14	  
	 Capital One Leverage Finance Corp.
	  	$	21,428,571.43	  	  	 	—  	  
	 Fifth Third Bank
	  	$	19,642,857.14	  	  	 	—  	  
	 Fifth Third, operating through its Canada branch
	  	 	—  	  	  	$	1,785,714.29	  
	 HSBC Bank USA, N.A.
	  	$	17,678,571.43	  	  	 	—  	  
	 HSBC Bank Canada
	  	 	—  	  	  	$	1,607,142.86	  
	 U.S. Bank National Association
	  	$	17,678,571.43	  	  	 	—  	  
	 U.S. Bank National Association, Canada Branch
	  	 	—  	  	  	$	1,607,142.86	  
	 RB International Finance (USA)
	  	$	15,714,285.71	  	  	$	1,428,571.43	  
		  	  
	  
	 	  	  
	  
	 
	 Total
	  	$	550,000,000.00	  	  	$	50,000,000.00	  
		  	  
	  
	 	  	  
	  
	 

 REVOLVING COMMITMENT SCHEDULE (POST-ALCAN AMENDMENT EFFECTIVE DATE) 

 

									
	 Lender
	  	U.S. Commitment	 	  	Multicurrency Commitment	 
	 JPMorgan Chase Bank N.A.
	  	$	112,500,000.00	  	  	 	—  	  
	 JPMorgan Chase Bank, N.A., Toronto Branch
	  	 	—  	  	  	$	22,500,000.00	  
	 Credit Agricole Corporate and Investment Bank
	  	$	67,500,000.00	  	  	$	7,500,000.00	  
	 Wells Fargo Bank N.A.
	  	$	67,500,000.00	  	  	 	—  	  
	 Wells Fargo Capital Finance Corporation Canada
	  	 	—  	  	  	$	7,500,000.00	  
	 Deutsche Bank AG New York Branch
	  	$	40,500,000.00	  	  	 	—  	  
	 Deutsche Bank AG Canada Branch
	  	 	—  	  	  	$	4,500,000.00	  
	 KeyBank National Association
	  	$	40,500,000.00	  	  	$	4,500,000.00	  
	 PNC Bank, National Association
	  	$	40,500,000.00	  	  	 	—  	  
	 PNC Bank Canada Branch
	  	 	—  	  	  	$	4,500,000.00	  
	 Bank of America, N.A.
	  	$	31,500,000.00	  	  	 	—  	  
	 Bank of America, N.A. (acting through its Canada Branch)
	  	 	—  	  	  	$	3,500,000.00	  
	 Branch Banking & Trust Company
	  	$	31,500,000.00	  	  	$	3,500,000.00	  
	 The Huntington National Bank
	  	$	35,000,000.00	  	  	 	—  	  
	 Compass Bank
	  	$	30,000,000.00	  	  	 	—  	  
	 Standard Chartered Bank
	  	$	27,000,000.00	  	  	$	3,000,000.00	  
	 Capital One Leverage Finance Corp.
	  	$	25,000,000.00	  	  	 	—  	  
	 Fifth Third Bank
	  	$	22,500,000.00	  	  	 	—  	  
	 Fifth Third, operating through its Canada branch
	  	 	—  	  	  	$	2,500,000.00	  
	 HSBC Bank USA, N.A.
	  	$	20,250,000.00	  	  	 	—  	  
	 HSBC Bank Canada
	  	 	—  	  	  	$	2,250,000.00	  
	 U.S. Bank National Association
	  	$	20,250,000.00	  	  	 	—  	  
	 U.S. Bank National Association, Canada Branch
	  	 	—  	  	  	$	2,250,000.00	  
	 RB International Finance (USA)
	  	$	18,000,000.00	  	  	$	2,000,000.00	  
		  	  
	  
	 	  	  
	  
	 
	 Total
	  	$	630,000,000.00	  	  	$	70,000,000.00EX-10.35

 Exhibit 10.35 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 AMENDED AND RESTATED 
 DISTRIBUTION AND SUPPLY AGREEMENT 
 This Amended and Restated
Distribution and Supply Agreement (this “Agreement”) is dated as of November 30, 2012 (the “Amended and Restated Effective Date”), by and among Santarus, Inc., a Delaware corporation (hereinafter referred to as
“Manufacturer”), and Prasco, LLC, an Ohio limited liability company (hereinafter referred to as “Distributor”). 
 Recitals 
 WHEREAS, Manufacturer and Distributor are parties to a
Distribution and Supply Agreement (the “Original Agreement”) originally made as of April 26, 2010 (the “Effective Date”). 
 WHEREAS, under the Original Agreement, Manufacturer has agreed to supply, and Distributor has agreed to purchase, distribute and sell, the Products (as defined herein) in the Territory in accordance with
the terms of the Original Agreement. 
 WHEREAS, Manufacturer and Distributor desire to amend and restate the Original Agreement
on the terms of this Agreement. 
 NOW THEREFORE, in consideration of the mutual covenants and consideration set forth herein,
the Parties hereto agree as follows: 
 ARTICLE 1 
 DEFINITIONS 
 As used in this Agreement, the following defined terms shall have the
meanings set out in this Article 1. 
 1.1 “Act” means the United States Federal Food, Drug, and
Cosmetic Act, as amended. 
 1.2 [***] 
 1.3 “Adverse Drug Experience” means any of the following: an “adverse drug experience,” a “life-threatening adverse drug experience,” a “serious adverse
drug experience,” or an “unexpected adverse drug experience,” as those terms are defined at 21 C.F.R. § 314.80. 
 1.4 “Affiliate” of a Party means any entity that directly or indirectly controls, is controlled by, or is under common control with, such Party. An entity shall be regarded as in
control of another entity if it owns or controls at least fifty percent (50%) of the equity securities of the subject entity entitled to vote in the election of directors (or, in the case of an entity that is not a corporation, for the election
of the corresponding managing authority), except that the term 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

 
“Affiliate” shall not include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to elect a majority of the board
of directors or other governing board, but is restricted from electing such majority by contract or otherwise, until such time as such restrictions are no longer in effect. 
 1.5 [***]  
 1.6 “Audited Party” has the meaning
given in Section 5.9(d) hereof. 
 1.7 “Auditing Party” has the meaning given in
Section 5.9(d) hereof. 
 1.8 [***] 
 1.9 [***]. 
 1.10 “Bankruptcy Event” means, with
respect to a Person, that such Person becomes insolvent, or voluntary or involuntary proceedings by or against such Person are instituted in bankruptcy or under any insolvency law, or a receiver or custodian is appointed for such Person, or
proceedings are instituted by or against such Person for corporate reorganization or the dissolution of such Person, which proceedings, if involuntary, shall not have been dismissed within sixty (60) days after the date of filing, or such
Person makes an assignment for the benefit of its creditors, or substantially all of the assets of such Person are seized or attached and not released within sixty (60) days thereafter. 

1.11 “Branded Products” means (a) the brand drug Zegerid® (omeprazole/sodium bicarbonate) Capsules 20mg/1100mg and 40mg/1100mg, manufactured and distributed in accordance
with NDA No. 21-849 and marketed under the Trademark; and (b) the brand drug Zegerid®
(omeprazole/sodium bicarbonate) Powder for Oral Suspension 20mg/1680mg and 40mg/1680mg, manufactured and distributed in accordance with NDA No. 21-636 and marketed under the Trademark. 

1.12 “Capsule Product” means omeprazole/sodium bicarbonate Product in capsule formulation sold to Distributor under this
Agreement. 
 1.13 “Change in Control” means (i) the liquidation or dissolution of a Party or the
sale or other transfer by a Party (excluding transfers to subsidiaries) of all or substantially all of its assets; or (ii) the occurrence of a tender offer, stock purchase, other stock acquisition, merger, consolidation, recapitalization,
reverse split, sale or transfer of assets or other transaction, as a result of which any person, entity or group (a) becomes the beneficial owner, directly or indirectly, of securities of a Party representing more than 50% of the ordinary
shares of such Party or representing more than 50% of the combined voting power with respect to the election of directors (or members of any other governing body) of such Party’s then outstanding securities, or (b) obtains the ability to
appoint a majority of the Board of Directors (or other governing body) of a Party, or obtains the ability to direct the operations or management of a Party or any successor to the business of a Party; provided, however, that for purposes of this
definition, the term “Party”, in the case of Distributor, shall be deemed to mean both Distributor and Scion Companies, LLC, the corporate parent of Distributor. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 2 

 1.14 “Commencement Date” has the meaning given in Section 2.1.

 1.15 “Commercially Reasonable Efforts” means, with respect to the efforts to be expended by any Party with
respect to any objective, those reasonable, diligent, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar objective under similar circumstances. “Commercially Reasonable Efforts” with
respect to a product shall mean those efforts and resources normally used by such Party with respect to a product owned or controlled by such Party, or to which such Party has similar rights, which product is of similar market potential and is at a
similar stage in its life as is the Product, taking into account issues of safety, efficacy, product profile, the competitiveness of the marketplace, the proprietary position of the Product, the regulatory structure involved, profitability of the
Product and other relevant commercial factors. 
 1.16 “Competitive Product” means a drug product, other
than the Products, that contains omeprazole and is marketed as a generic product AB rated to and substitutable for any of the Branded Products. 
 1.17 “Confidential Information” means all proprietary materials, data or other information (whether or not patentable) regarding a Party’s know how, products, business
information or objectives, that is designated as confidential in writing by the disclosing Party, whether by letter or by the use of an appropriate stamp or legend, prior to or at the time any such material, data or other information is disclosed by
the disclosing Party to the other Party. Notwithstanding the foregoing, materials, data or other information that are disclosed by a Party in writing without an appropriate letter, stamp or legend, or that are orally, electronically or visually
disclosed by a Party, shall constitute Confidential Information of such Party if (a) such Party, within thirty (30) days after such disclosure, delivers to the receiving Party a written document or documents describing the materials, data
or other information, indicating that such materials, data or other information constitute Confidential Information, and referencing the place and date of such oral, visual, electronic or written disclosure and the names of the persons to whom such
disclosure was made, or (b) such materials, data or other information are of the type that is customarily considered to be confidential information by persons engaged in activities that are substantially similar to the activities being engaged
in by the Parties. 
 1.18 “Distributor Discretionary Change” has the meaning given in
Section 4.2(b) hereof. 
 1.19 “Event of Default” has the meaning given in Section 10.4
hereof. 
 1.20 “FDA” means the United States Food and Drug Administration. 

1.21 “First Commercial Sale” means the date of the first sale of a Product in the Territory by Distributor
pursuant to the terms of this Agreement. 
 1.22 “Force Majeure Event” has the meaning given in
Section 10.7 hereof. 
 1.23 “Initial Term” has the meaning given in Section 10.1 hereof.

 1.24 “Invoice Supply Price” has the meaning given in Section 3.2 hereof. 

  
 3 

 1.25 [***] 
 1.26 “Manufacturer Discretionary Change” has the meaning given in Section 4.2(a) hereof. 
 1.27 “NDA” means a New Drug Application pursuant to Section 505 of the Act (21 U.S.C. Section 355), or the applicable regulations (21 CFR Part 314), including any
supplements, amendments or modifications submitted to or required by the FDA or any successor application or procedure for approval to market a pharmaceutical product. 
 1.28 “NDC#” means a unique 3-segment number that identifies the labeler/vendor, the product and the trade package size. 

1.29 [***] 
 1.30 “Net Sales” means the gross amount billed or invoiced to independent Third Party customers (including taxes) for sales of Products on an SKU basis, less deductions for
(a) [***] (b) [***], and (c) taxes charged to the customer and itemized on the invoice and directly related to the sale of Products, all determined in accordance with United States generally accepted
accounting principles consistently applied. Products shall be considered sold as of the date title passes to the customer (upon delivery). 
 1.31 “Party” means Manufacturer or Distributor, as the case may be, and “Parties” means Manufacturer and Distributor. 

1.32 “Period 1,” “Period 2”, and “Period 3” each have the meanings given in Section 3.2(b) hereof.

 1.33 “Person” means any individual, corporation, partnership, limited liability company, joint
venture, association, trust, unincorporated organization or other entity. 
 1.34 “Product Listing”
means filing with the FDA a list of drugs in commercial distribution as required by law. 
 1.35
“Products” means (a) omeprazole/sodium bicarbonate capsules 20mg/1100mg and 40mg/1100mg; and (b) omeprazole/sodium bicarbonate powder for oral suspension 20mg/1680mg and 40mg/1680mg, each in finished final packaged
form that are manufactured by or on behalf of Manufacturer for sale to and subsequent resale by Distributor in the Territory. In addition to the foregoing, the term Products shall also include any other dosage formulation of omeprazole that
Manufacturer has elected to include in this Agreement pursuant to Section 2.2. 
 1.36 “Regulatory
Agency” means the FDA and the regulatory agency or notified body in a country that performs the same or equivalent function as the FDA in the United States. Any reference to a rule or requirement of the FDA herein shall refer, if the
circumstances make it applicable, to the equivalent rule or requirement of any other Regulatory Agency. 
 1.37
“Remaining Supply Price” has the meaning given in Section 3.4 hereof. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 4 

 1.38 “Renewal Term” has the meaning given in Section 10.1
hereof. 
 1.39 “Required Manufacturing Change” has the meaning given in Section 4.1 hereof.

 1.40 “Rolling Forecast” has the meaning given in Section 5.5(a) hereof. 

1.41 “Sale Date” means the date of sale of Capsule Product by Distributor to a Third Party. 

1.42 “SKU” means each of the following unit configurations of the Products: (a) omeprazole/sodium
bicarbonate capsules 20mg/1100mg (30-count bottle); (b) omeprazole/sodium bicarbonate capsules 40mg/1100mg (30-count bottle); (c) omeprazole/sodium bicarbonate powder for oral suspension 20mg/1680mg (carton of 30 single dose packets); and
(d) omeprazole/sodium bicarbonate powder for oral suspension 40mg/1680mg (carton of 30 single dose packets). 
 1.43
“Specifications” means the specifications for each Product contained in the NDA for the Branded Products. 

1.44 “Supply Price” has the meaning given in Section 3.1 hereof. 

1.45 “Term” has the meaning given in Section 10.1 hereof. 

1.46 “Territory” means the United States of America and its territories and possessions. 

1.47 “Third Party(ies)” means any Person other than the Parties or their respective Affiliates. 

1.48 “Third Party Vendors” has the meaning given in Section 2.10. 

1.49 “Trademark” means Zegerid®. 
 1.50 [***] 

1.51 “WAC” means, with respect to any Capsule Product, the published list price of the corresponding Branded Product to
wholesalers as determined by Manufacturer from time to time, without taking into account wholesaler prompt payment terms, introductory launch terms or other discounts, rebates, chargebacks or fees. 

ARTICLE 2 

DISTRIBUTION RIGHTS AND OBLIGATIONS 
 2.1 Commencement Date; First Commercial Sale. 
 (a) The
Parties acknowledge that Manufacturer has multiple SKUs of the Products and may elect to launch individual SKUs of the Products at different times. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 5 

 (b) Manufacturer shall have the sole right and discretion to determine if and when to
launch each individual SKU of the Products. If Manufacturer decides to launch an SKU of the Products, Manufacturer shall provide Distributor with written notice specifying a date for Distributor to commence distributing and marketing such SKU. A
notice delivered by Manufacturer under this Section 2.1(b) for an SKU of the Products is referred to herein as a “Commencement Notice” with respect to such SKU of the Products, and the date specified in a Commencement Notice is
referred to herein as the “Commencement Date” with respect to such SKU of the Products. 
 (c) Effective as of
the Commencement Date with respect to each SKU of the Products, Manufacturer grants to Distributor a nonsublicensable, nontransferable license under the NDA for the applicable Branded Product to distribute and sell such SKU of the Products in the
Territory as a generic product AB rated to and substitutable for the applicable Branded Product. Upon delivery of the Commencement Notice for an SKU of the Products, Manufacturer shall supply such SKU of the Products to Distributor
[***], and Distributor shall distribute and market such SKU of the Products in the Territory as a generic product commencing as of the Commencement Date, in each case in accordance with this Agreement. Until the Commencement Date with
respect to an SKU of the Products, Distributor shall have no right to distribute, advertise, promote or sell such SKU of the Products, [***]. [***] 
 (d) Distributor shall use Commercially Reasonable Efforts to launch each SKU of the Products on the applicable Commencement Date; provided, however, and subject to Section 10.7, such launch
shall occur not later than [***]. [***], Distributor shall send written notice to Manufacturer specifying the date of the First Commercial Sale of such SKU of the Products. In addition, Distributor shall confirm the date
of First Commercial Sale via email (to an email address designated by Manufacturer) [***]. 
 2.2
Additional Product. During the Term, Manufacturer may specify additional dosage forms of omeprazole, either as a single entity or in combination, to be included in the definition of “Product” and to be distributed and sold by
Distributor in accordance with this Agreement. If Manufacturer elects to include such other dosage forms, Manufacturer shall provide Distributor prior written notice of such election (the “Added Product Election”), together with the
Invoice Supply Price for such added Product. The Invoice Supply Price for such added Product shall be determined in accordance with the same criteria as the Invoice Supply Prices set forth in Exhibit 3.2. Following such Added Product
Election, such added Product shall be deemed a “Product” for all purposes hereunder. Distributor shall launch such added Products [***]. 
 2.3 Supply and Commercial Exploitation. Distributor shall purchase all of its requirements of the Products exclusively from Manufacturer in accordance with this Agreement. Distributor shall
use Commercially Reasonable Efforts to distribute, promote and expand the sale of the Products as generic products in the Territory, and in performing such activities, Distributor shall devote the same level of effort to Manufacturer and the
Products as it does for its other customers and products. In promoting and distributing the Products, Distributor shall not use the Trademark or any other trademark or trade name, except that Distributor may (a) use the Trademark on promotional
materials to the extent necessary to indicate that the Products are substitutable for the Branded Products and are “authorized generics” of the Branded Products, and 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 6 

 
(b) identify itself as the distributor of the Product using its “Prasco” trade name and trade dress; provided, however, that all such promotional materials shall be approved by
Manufacturer in accordance with Section 6.2. 
 2.4 [***] 

2.5 Distribution Obligations. Distributor shall: (i) store, handle and distribute its inventory of the Products in
clean and sanitary conditions as required to maintain the quality and traceability of the Products, and in accordance with the labeling for the Products; (ii) not alter the Products in any manner; (iii) comply with the Act and all other
applicable federal, state and local food, health and other relevant laws and regulations within the Territory in connection with its storage, handling, distribution and sale of the Products; (iv) not promote or market the Products in any manner
which is inconsistent with the labeling of the Products or applicable laws and regulations (including without limitation, 21 CFR Section 201), or otherwise make any false or misleading representations to customers or others regarding the
Products. 
 2.6 Solicitation Outside Territory. Distributor shall not, and Distributor shall cause its
Affiliates to not (i) solicit or accept orders for sales of any Product or Products to any existing or prospective customer outside the Territory, (ii) deliver or tender (or cause to be delivered or tendered) any Product or Products
outside of the Territory, or (iii) sell any Product or Products to, or solicit any sales from, a customer if Distributor knows or has reason to know that such customer intends to resell the Products outside of the Territory. 

2.7 Pricing. Distributor shall have sole discretion in establishing the prices at which Distributor sells the Products.
[***] 
 2.8 Reservation of Rights. Except as expressly provided in this Agreement, Manufacturer is
not granting to Distributor any right, title or interest, whether express or implied, under any intellectual property right or other right that Manufacturer or its Affiliates may own or otherwise control. Nothing in this Agreement shall preclude or
prevent Manufacturer or its Affiliates from manufacturing, marketing or selling the Branded Products (either by itself or through a Third Party) in the Territory. Except as set forth in Section 2.1, nothing contained in this Agreement
shall grant (or be construed as granting) to Distributor any right, title or interest in, to or under any NDA held in the name of Manufacturer, or any supplement thereto, or any other intellectual property right owned or controlled by Manufacturer.

 2.9 NDC#; Manufacturer. Distributor shall distribute and sell the Products using only an NDC# that reflects
Distributor as the distributing and selling party. Distributor shall take all actions necessary to obtain such new NDC# prior to the first Commencement Date. Manufacturer shall be listed as the manufacturer on the label for the Products. 

2.10 Contract Manufacture. Distributor acknowledges that Manufacturer may use an Affiliate or one or more Third Parties to
supply, contract manufacture or package the Products (collectively, “Third Party Vendors”). 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 7 

 2.11 Compliance with Laws. Each of Distributor and Manufacturer shall perform
its obligations under this Agreement in all material respects in compliance with applicable laws, rules and regulations. 

2.12 [***] 
 2.13 Settlement of Patent Litigation. Nothing in this Agreement shall be deemed to prohibit Manufacturer from settling any patent litigation relating to the Branded Products or
authorizing a Third Party that is a party to such a settlement to sell, market or distribute a Competitive Product (including an authorized generic of the Branded Products) in the Territory. 

ARTICLE 3 

FINANCIAL PROVISIONS 
 3.1 Supply Price. Following the first Commencement Date, and during the remaining Term, Distributor shall pay Manufacturer the Supply Price for the Products on an SKU basis, consisting of
the Invoice Supply Price, [***] (if and as applicable), [***] and any [***]. 
 3.2 Invoice Supply
Price[***]. 
 (a) Invoice Supply Price. The provisions in this Section 3.2(a) shall apply for each
Product. [***]. With respect to each Product, the price determined pursuant to Section 3.2(a) is referred to in this Agreement as the “Invoice Supply Price,” [***] 

(i) The initial Invoice Supply Price for each Product is set forth in Exhibit 3.2. [***] Notwithstanding the
foregoing, if the First Commercial Sale of a Product has not occurred by [***], then the initial Invoice Supply Price for each such Product shall be adjusted as of [***] and thereafter as contemplated by Section 3.2(a)(ii),
[***]. 
 (ii) [***] 
 (iii) In addition, to the extent that Manufacturer [***]. 

(b) [***] 
 (i) [***] 
 (ii) [***] 

(iii) [***] 
 (c) [***] 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 8 

 (d) Notice of Increases in WAC. Manufacturer shall notify Distributor in
writing of increases in WAC of the Capsule Product no later than the date the increase is published. 
 3.3 Payment of
Invoice Supply Price. 
 (a) Manufacturer shall invoice Distributor for the Invoice Supply Price together with,
or promptly after, each shipment of Product to Distributor, [***]. Distributor shall pay Manufacturer’s invoices for the Invoice Supply Price of each Product: (A) within [***] days after the date of First Commercial
Sale of the Product if Manufacturer ships the Product prior to such First Commercial Sale or if Manufacturer ships the Product within [***] days after such First Commercial Sale; and (B) within [***] days from the date of invoice
for shipments of such Product thereafter. For all Products added under Section 2.2, Distributor shall pay Manufacturer’s invoices for each Product: (I) within [***] days after the date of the First Commercial Sale of the
Product if Manufacturer ships the Product prior to such First Commercial Sale or if Manufacturer ships the Product within [***] days after such First Commercial Sale; and (II) within [***] days from the date of invoice for shipments of
such Product thereafter. The date of each invoice for [***] shall be the date of First Commercial Sale of such [***], and the date of each invoice for other Products shall be the date of shipment of such Products to Distributor.

 (b) Distributor shall make all payments without deduction, deferment, set-off, lien or counterclaim of any nature,
other than for rejected or returned goods for which Manufacturer has issued a credit acknowledgment. 
 3.4 [***]

 (a) Following the first Commencement Date, and during the remaining Term, Distributor shall pay Manufacturer
[***], and shall make such payments in accordance with Section 3.5. For clarity, Manufacturer shall not be required to pay Distributor for any negative Net Distributable Profits, except as otherwise provided in Section 3.5(c). For
purposes hereof, a “calendar month” is measured as follows with respect to each SKU of the Products that has a different date of First Commercial Sale: (i) for the first calendar month, the stub period beginning on the date of the
First Commercial Sale of such Product and ending on the last day of the calendar month in which the First Commercial Sale occurs; (ii) for the next succeeding months, the full calendar month period; and (iii) for the final calendar month,
the stub period beginning on the first day of the calendar month and ending on the termination or expiration of this Agreement. 

(b) The Parties acknowledge that the calculations of Net Sales and Net Distributable Profits will include accruals based on
estimates that Distributor believes are reasonable and that actual results likely will differ from these accruals. [***], Distributor shall provide to Manufacturer (in accordance with the Accrual Rollforward Report included in Exhibit
3.4(b)) a rollforward of accrual activity [***]. Each Accrual Rollforward Report shall show accruals at the beginning of the [***] period, additions to accruals during that period, actual charges against accruals during that
period, any adjustments to accruals deemed necessary by Distributor, and ending accruals recorded by Distributor at the end of that period. Upon the 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 9 

 
expiration or termination of this Agreement, Distributor shall continue to provide Manufacturer with an Accrual Rollforward Report as provided in this Section 3.4(b) until all adjustments to
existing accruals have been determined, or until such time as the parties mutually agree in accordance with Section 3.5(c)(iv). 
 (c) [***] 
 3.5 Payment of [***]. During the period
commencing on the First Commercial Sale of a Product and continuing thereafter as described further below: 
 (a) Within
[***] days after the end of each calendar month, Distributor shall deliver to Manufacturer (i) a written report showing with respect to the immediately preceding month, inventory of Product in Distributor’s distribution facilities
as of the first and last days of such month, and units of Product received and shipped during such month (all in accordance with the report included in Exhibit 3.5(a)(i)), (ii) a written report in the form of Exhibit
3.5(a)(ii), completed with respect to the prior month, including the calculation [***] for such calendar month and [***] for such calendar month, and (iii) with respect to each full or partial calendar month
during Period 1 or Period 2, a written report showing the number of units of each strength of Capsule Product sold or transferred by Distributor to Third Parties during such month having a Sale Date during Period 1 or Period 2 and a calculation of
[***] for such units. 
 (b) Within [***] days after the end of each calendar month, Distributor
shall remit the amount due [***] for Capsule Product having a Sale Date during such month by wire transfer in U.S. dollars to the credit of such bank account as shall be designated in advance by Manufacturer. 

(c) Notwithstanding any provision of this Agreement to the contrary: 

(i) If the sum of [***] for any calendar month is greater than zero, Distributor shall remit such amount due to
Manufacturer for such calendar month by wire transfer in U.S. dollars to the credit of such bank account as shall be designated in advance by Manufacturer. Such payment shall be made within [***] days after the end of the calendar month in
which the First Commercial Sale of a Product occurs (provided that such time period may be extended to [***] days with regard to the amount of Product sold during such calendar month for which Distributor has not received payment as of the
[***] day), and within [***] days after the end of each calendar month thereafter. 
 (ii) If for any
reason [***] under this Section 3.5(c)(ii)) for any calendar month is less than zero, Manufacturer shall not be required to pay Distributor for such negative amount, and such negative amount shall be carried forward to the next month and
applied against future payments of [***] until such time that such amount is greater than zero. 
 (iii) Upon the
expiration or termination of this Agreement, if there are any amounts carried forward under Section 3.5(c)(ii) that were not applied against future payments [***] in accordance with this Section 3.5(c) by the last calendar month
during the Term, Manufacturer shall pay such amounts to Distributor within [***] days after the 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 10 

 
expiration or termination of this Agreement. Nothing contained in this Agreement shall require Manufacturer to pay any disputed amounts set forth in any report or notice provided by Distributor,
or otherwise constitute a waiver of any right of Manufacturer to dispute the amounts set forth in such report or notice. 

(iv) Within [***] days after the end of each calendar quarter after expiration or termination of this Agreement until such
time as the parties mutually agree, Distributor shall prepare and deliver to Manufacturer the report contemplated by Section 3.5(a)(ii) based on continuing Accrual Rollforward Reports provided by Distributor in accordance with
Section 3.4(b), and shall reconcile any underpayments or overpayments resulting therefrom. Within [***] days following receipt of such report, in the case of an underpayment, Distributor shall remit payment to Manufacturer, and,
in the case of an overpayment, Manufacturer shall remit payment to Distributor. 
 (v) In the event Distributor provides
any credits to customers as a result of price increases relating to the Capsule Product or otherwise, the reports provided by Distributor to Manufacturer pursuant to Section 3.5(a)(ii) shall also include a reconciliation of such credits against
purchases of Capsule Product made by such customers (in a blinded and aggregated format) from and after the date such credits were provided. The form of such reconciliation report shall be agreed upon by the parties in good faith. 

(d) Within [***] days after the first Commencement Date and within [***] days after the end of each calendar year
thereafter, Distributor shall submit to Manufacturer [***]. In addition, Distributor shall provide [***] upon the reasonable request of Manufacturer. 
 (e) Within [***] business days after each full or partial calendar week during Period 1 or Period 2, Distributor shall deliver to Manufacturer [***]. 

(f) Distributor shall make all payments without deduction, deferment, set-off, lien or counterclaim of any nature, except as
otherwise expressly provided herein. 
 3.6 Taxes and Withholding. Distributor shall make all payments to
Manufacturer under this Agreement without any deduction or withholding for, or on account of, any tax. 
 3.7
Currency. All amounts hereunder, including, without limitation, Net Sales, expense amounts and the amounts due to Manufacturer hereunder, shall be expressed in U.S. dollars. 

3.8 Maintenance of Records; Audit. Distributor shall maintain, and shall require its Affiliates to maintain, complete and
accurate books and records in connection with the handling, sale, and distribution of all Products hereunder, as necessary to allow the accurate calculation consistent with generally accepted accounting principles of the amounts due to Manufacturer,
the reporting obligations contemplated herein, and compliance with the terms of this Agreement, and Distributor shall maintain such books and records for a period of at least [***] after the end of the calendar year in which they were
generated, or for such longer period as may be required by law. Once per calendar year during the Term, Manufacturer shall have the right to engage an 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 11 

 
independent accounting firm reasonably acceptable to Distributor, at Manufacturer’s expense, which shall have the right to examine in confidence the relevant books and records as may be
reasonably necessary to determine or verify the amount of payments due hereunder and compliance with obligations hereof. Such accounting firm shall conduct such examination, and Distributor shall make such books and records available, during normal
business hours at the facility(ies) where such books and records are maintained. Each such examination shall be limited to pertinent books and records for any year ending not more than [***] prior to the date of request; provided that
Manufacturer shall not be permitted to audit the same period of time more than once. Before permitting such independent accounting firm to have access to such books and records, Distributor may require such independent accounting firm and its
personnel involved in such audit to sign a confidentiality agreement (in form and substance reasonably acceptable to Distributor) as to any Confidential Information which is to be provided to such accounting firm or to which such accounting firm
will have access while conducting the audit under this Section. The independent accounting firm will prepare and provide to each Party a written report stating whether the reports submitted and amounts paid are correct or incorrect and the amounts
of any discrepancies. If there was an underpayment by Distributor hereunder, Distributor shall promptly (but in no event later than thirty (30) days after its receipt of the independent auditor’s report so concluding) make payment to
Manufacturer of any shortfall by wire transfer in U.S. dollars, including interest calculated in accordance with Section 3.9. If there was an overpayment by Distributor hereunder, Manufacturer shall promptly (but in no event later than thirty
(30) days after Manufacturer’s receipt of the independent auditor’s report so concluding) refund to Distributor the excess amount by wire transfer in U.S. dollars. In the event of any underpayment by Distributor resulting in a
cumulative discrepancy during any calendar year in excess of the greater of (i) 5% or (ii) one hundred thousand dollars ($100,000.00), all costs of the audit, including the expenses of the independent accounting firm, shall be borne and
promptly paid by Distributor. 
 3.9 Interest on Late Payments. If any payment under this Agreement is
late, interest shall accrue on the past due amount at a rate equal to the lesser of (a) [***] percent per annum, and (b) the maximum rate permitted by law. Time for any payments hereunder shall be of the essence. 

ARTICLE 4 

MARKET REQUIREMENTS AND SPECIFICATIONS 
 4.1 Mandatory Changes to Specifications. Manufacturer shall use Commercially Reasonable Efforts to make changes to the Specifications that are required by applicable law (a “Required
Manufacturing Change”). To the extent reasonably practicable and in any event prior to shipment, Manufacturer shall notify Distributor of such proposed changes prior to implementing such changes. [***] 

4.2 Discretionary Changes to Specifications. 
 (a) Manufacturer shall be permitted to make changes to the Specifications or manufacturing processes that are not Required Manufacturing Changes (a 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 12 

 
“Manufacturer Discretionary Change”); provided, however, that Manufacturer shall provide Distributor at least ninety (90) days prior notice of any such Manufacturer Discretionary
Change that requires pre-approval from the FDA and at least thirty (30) days prior notice of any other such Manufacturer Discretionary Changes; and provided further that Manufacturer shall comply with all applicable legal requirements
concerning any Manufacturer Discretionary Change. [***] At any time during the Term, Manufacturer may in its sole discretion, without the consent of Distributor but with the applicable prior notice to Distributor described above,
change the manufacturer used in the manufacturing or labeling of Products and change any suppliers of raw materials or components used in making such Products. Distributor shall cooperate with Manufacturer in a reasonable manner to effect such
change or transfer. Manufacturer shall be responsible for making any required regulatory filings with respect to such change in supplier or manufacturing facility and shall be responsible for obtaining all approvals in connection therewith.

 (b) Subject to Section 6.1, Distributor shall be permitted to make changes to the labeling that are not Required
Manufacturing Changes (a “Distributor Discretionary Change”), subject to Manufacturer’s prior written consent; provided, however, that Distributor shall provide Manufacturer at least ninety (90) days prior notice of any such
Distributor Discretionary Change, Manufacturer shall then work diligently with Distributor and any Third Party Vendors to implement such change, and Distributor shall comply, and take all actions necessary for Manufacturer to comply with all
applicable legal requirements concerning any Distributor Discretionary Change. [***] 
 4.3 Regulatory
Filings; Communication with Regulatory Agency. Manufacturer will have control over, and authority and responsibility for, monitoring and coordinating all maintenance of, regulatory actions with respect to, and communications and filings with
and submissions to, any Regulatory Agency with respect to the NDA for the Products and the distribution and sale of the Products under this Agreement, including making all filings with the FDA required for Product Listing, any Required Manufacturing
Change or Manufacturer Discretionary Change, as well as reporting of Adverse Drug Experiences. Manufacturer shall use Commercially Reasonable Efforts to make such filings with applicable Regulatory Agencies as necessary for Manufacturer to carry out
its obligations under this Agreement. In the case of the Product Listing, Distributor shall assist Manufacturer in preparing the required form for filing by Manufacturer. Notwithstanding the foregoing, Distributor shall be solely responsible for
communications and filings with and submissions to any Regulatory Agency or other federal, state or local governmental authority concerning Product sales, prices, discounts, rebates, fees, charge-backs, and other payments associated with
Distributor’s distribution and sale of Products under this Agreement, including without limitation, all reporting, and disclosure obligations under the Medicaid Drug Rebate Program (Monthly and Quarterly Average Manufacturer Price, Baseline
Average Manufacturer Price, and Rebate Per Unit), Medicare Part B (Quarterly Average Sales Price), the Veteran’s HealthCare Act 602 (Public Health Service 340B Quarterly Ceiling Price), the Veteran’s HealthCare Act 603 (Quarterly and
Annual Non-Federal Average Manufacturer Price and Federal Ceiling Price), and Federal Supply Schedule Contract Prices. Distributor shall also cooperate fully with Manufacturer and shall timely supply all data and information requested by
Manufacturer to enable Manufacturer to comply with any applicable federal, state or local reporting and disclosure requirements concerning Manufacturer’s supply of Products to Distributor under this Agreement. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 13 

 4.4 Distributor Communication with Regulatory Agency. If Distributor
reasonably concludes, after consultation with its regulatory counsel, that it is necessary or advisable for Distributor to communicate with a Regulatory Agency regarding Distributor’s activities under this Agreement, then Distributor shall so
advise Manufacturer reasonably in advance and shall provide Manufacturer with copies of all correspondence between Distributor and the applicable Regulatory Agency. Distributor shall provide Manufacturer with copies of all correspondence, documents
and materials received from a Regulatory Agency concerning any Product or any activities under this Agreement. Distributor shall provide Manufacturer with copies of any proposed correspondence or communications of any kind to a Regulatory Agency
that relates to any Product or any activities under this Agreement at least seven (7) days before the submission of such correspondence. Distributor shall adopt all reasonable suggestions and recommendations of Manufacturer concerning any
meeting or written or oral communication with such Regulatory Agency. 
 4.5 Regulatory Cooperation. Each Party
shall provide the other with all reasonable assistance and take all actions reasonably needed to enable such other Party to comply with any law applicable to such other Party’s activities under this Agreement. Except as otherwise provided in
Article 7, such assistance and actions shall include, without limitation, informing the other Party within forty-eight (48) hours of receiving any information that: 
 (a) Raises any material concerns regarding the safety or efficacy of any Product; 
 (b) Indicates or suggests a potential material liability for either Party to Third Parties arising in connection with any Product; 

(c) Is reasonably likely to lead to a recall or market withdrawal of any Product in the Territory; or 

(d) Concerns any material investigation, inspection, detention, seizure or injunction involving any Product by any Regulatory
Agency in the Territory. 
 Manufacturer and Distributor shall, in each such case, jointly determine whether subsequent notification to a
Regulatory Agency is required, and if necessary, which Party shall provide such notification. Except as otherwise provided in Article 7, if the parties disagree on whether to notify a Regulatory Agency, the position of Manufacturer shall control.

 4.6 Payment of Rebates on the Products. Distributor shall be solely responsible for all federal, state and
local government and private purchasing, pricing or reimbursement programs with respect to the Products sold by Distributor, including taking all necessary and proper steps to execute agreements and file other appropriate reports and other documents
with governmental and private entities. Distributor shall be solely responsible for payment and processing of all rebates, whether required by contract or local, state or federal law, for the Products sold by Distributor. 

4.7 Product Returns. Except as otherwise set forth in Article 5 (and subject to Section 1.30), Distributor
shall be solely responsible for handling any Product returns, including responsibility for destruction and any associated costs. 

  
 14 

 ARTICLE 5 
 ORDERS AND TERMS 
 5.1 Delivery Terms; Title Passage

 (a) [***], (i) Manufacturer shall deliver all quantities of Product to Distributor FCA (Incoterms 2000)
Manufacturer’s manufacturing facility, warehouse or such other facility mutually agreed to by the Parties, (ii) risk of loss and title shall pass to Distributor once the Products are placed on the loading dock of Manufacturer’s
facility, and (iii) [***]. 
 (b) [***] 

5.2 Shipping Documentation. All shipments of Products shall be accompanied by a packing slip that describes the Products
and states the purchase order number. Manufacturer shall supply with each shipment a Certificate of Analysis for each lot of the Products included in the shipment. Each Certificate of Analysis shall include, at a minimum, the Product name, batch
number, date of manufacture, analytical test results, product specifications, microbiological test results (if applicable), and certification by Manufacturer’s Quality Assurance that all Specifications have been met as of the time of shipment
and that the Product was produced and tested in accordance with cGMP requirements. 
 5.3 Governing Terms.
To the extent there is any conflict or inconsistency between this Agreement and any purchase order, purchase order release, confirmation, acceptance or any similar document, the terms of this Agreement shall govern. 

5.4 Other Costs. Except as expressly set forth in this Agreement, Distributor shall be solely responsible for all costs and
expenses related to the marketing, sale and distribution of Products in the Territory. 
 5.5 Forecasts and Purchase
Orders. 
 (a) Forecasts. Commencing on the Effective Date (or such later date as the parties may mutually
agree) with respect to quantities required for launch of the Products [***], and on the [***] of each calendar month following the first Commencement Date, Distributor shall provide to Manufacturer a non-binding, good faith written
estimate (the “Rolling Forecast”) by month of Distributor’s quantity requirements for Products by SKU for next [***]. For example, Distributor’s Rolling Forecast provided on [***] of any year shall cover the period
from [***] through [***] of that year. 
 (b) Ongoing Firm Orders. Accompanying each Rolling
Forecast, Distributor shall place [***] binding purchase orders for Products for the [***] month contained in such Rolling Forecast by written or electronic purchase order to Manufacturer (or by any other means agreed to by the
Parties), except that the binding purchase orders accompanying the first Rolling Forecast shall cover the first [***] contained in such Rolling Forecast. Distributor shall be required to purchase at a minimum [***] of the amount of
Products forecasted for the [***] of 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 15 

 
each Rolling Forecast subject to binding purchase orders, except that [***]. Each purchase order shall specify the quantity and type of each Product by SKU and delivery schedule.
Orders shall be placed in accordance with the batch sizes and minimum order quantities set forth on Exhibit 5.5(b) hereto, which may be amended by written notice from Manufacturer from time to time. Manufacturer shall use its Commercially
Reasonable Efforts to fulfill purchase orders submitted to Manufacturer which meet the volume requirements set forth in this Section. [***] 
 (c) Dating. All Products supplied by Manufacturer shall, upon receipt by Distributor or its designee, have dating no less than [***] months prior to expiration (in the case of
omeprazole/sodium bicarbonate capsules 40mg/1100mg and omeprazole/sodium bicarbonate powder for oral suspension 40mg/1680mg) and no less than [***] months prior to expiration (in the case of omeprazole/sodium bicarbonate capsules 20mg/1100mg
and omeprazole/sodium bicarbonate powder for oral suspension 20mg/1680mg). Supply of any Products having shorter dating shall be subject to the written consent of Distributor, which shall not be unreasonably withheld. 

(d) Delivery. Any shipment delivered that is within [***] of the quantity ordered will be considered as meeting such
order quantity, and any shipment delivered on a date within [***] of the delivery date specified on the purchase order will be considered as delivered on time. In addition, in no event shall Manufacturer be deemed in breach or default under
this Agreement if Distributor has sufficient inventory to cover any shortfalls under purchase orders. 
 5.6 Acceptance
and Rejection and Product Defects. 
 (a) Delivery of any Products by Manufacturer to Distributor shall
constitute a certification by Manufacturer that such Products conform to the warranties in Section 5.7(a). Distributor shall have thirty (30) days after receipt of each shipment of Products to determine if such Products conform to such
warranties and to accept or reject any of such Products that fail to conform to such warranties. Distributor shall submit any claims for failure to so conform (“Claims”) in writing to Manufacturer within such thirty (30) day period
describing in detail the nonconforming characteristics of the Products. Distributor shall be deemed to have accepted any Products if it fails to submit a Claim during such thirty (30) day period. 

(b) If Distributor submits a Claim and Manufacturer does not agree with the Claim, the Parties shall submit the Products in
question to a mutually agreed independent party that has the capability of testing the Products to determine whether they comply with the warranties in Section 5.7(a). The determination of such independent party shall be binding on the Parties.
The losing Party shall bear all costs and expenses related to such testing. Manufacturer shall be deemed to have agreed with a Claim if it fails to give Distributor objection in writing to the Claim within fifteen (15) days after it receives
the Claim. 
 (c) If Manufacturer agrees with the Claim, or if Manufacturer disagrees with the Claim but an independent
party determines under Section 5.6(b) that the Products do not comply with the warranties in Section 5.7(a), then Manufacturer shall (a) credit Distributor the Invoice Supply Price for the Products in question as promptly as
reasonably 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 16 

 
possible (but in any event within fifteen (15) days), (b) instruct Distributor whether to return or destroy the Products in question, and (c) provide Distributor with replacement
Products as promptly as reasonably possible (invoiced in accordance with Section 3.3 for payment by Distributor). Manufacturer shall pay for all costs of returning or destroying non-conforming Products and shall bear the risk of loss for such
Products from the time they leave Distributor’s premises for return delivery or destruction. In addition, Manufacturer shall pay for all freight and insurance costs of sending the replacement Products. 

5.7 Product Warranty. 
 (a) Manufacturer warrants that (i) [***], and (ii) upon delivery at the shipping point of all other Product supplied to Distributor in accordance with Section 5.1(a), such
Product (i) shall comply with the Specifications, (ii) shall have been manufactured in material compliance with all applicable laws, rules and regulations, including current good manufacturing practices, (iii) shall not be adulterated
or misbranded within the meaning of the Act, and (iv) may be introduced into interstate commerce pursuant to the Act. 

(b) If any Product accepted by Distributor does not conform to the above warranties, including, without limitation, in the context
of any recall of, or other corrective actions with respect to, the Products, Manufacturer shall be obligated, at its option, to promptly (but in any event within [***] days after Distributor notifies Manufacturer of the non-conformity)
replace such Product at its own expense and ship such replacement Product back to either Distributor or the applicable customer at its own expense, or to credit to Distributor the Invoice Supply Price for the Product (and [***] paid or
payable by Distributor if Distributor has sold or transferred the Capsule Product to a Third Party). If customers return defective Products to Distributor that are covered by the foregoing warranties, at Manufacturer’s option, Distributor shall
either (i) destroy such Products, or (ii) ship them to Manufacturer at Manufacturer’s expense for such replacement. If the Parties disagree on whether any Product fails to comply with the warranties in Section 5.7(a), the Parties
shall resolve the disagreement as provided in Section 5.6(b). 
 (c) Warranty claims shall not apply to damaged
Products to the extent such damage is caused in whole or in part by Distributor’s negligence or breach of this Agreement or use, handling, or storage by any party other than Manufacturer [***] that is not in accordance with
Manufacturer’s instructions (consistent with current good manufacturing practices) or the Product labeling or that constitutes improper treatment. 
 5.8 Sole Remedy. Except as provided in Section 9.1(a) and Section 7.2, the provisions of Section 5.6 and Section 5.7 above shall be the sole and exclusive remedy
available to Distributor with respect to any Product that fails to meet the warranties in Section 5.7(a) 
 5.9
Inspection and Audit. 
 (a) From and after the first Commencement Date, Distributor shall have the right,
upon reasonable advance notice and during regular business hours, to have a Third Party reasonably acceptable to Manufacturer inspect and audit the facilities being used by Manufacturer for production of Products (including those of any Third Party
Vendor used by 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 17 

 
Manufacturer) to assure compliance by Manufacturer and/or the Third Party Vendor with prevailing FDA or other Regulatory Agency good manufacturing practices. Manufacturer shall be entitled to
accompany Distributor on any such audit. 
 (b) From and after the first Commencement Date, Manufacturer shall have the
right, upon reasonable advance notice and during regular business hours, to inspect and audit the facilities being used by or for the benefit of Distributor for the handling, storage and distribution of Products (including those of any subcontractor
or agent used by Distributor) to assure compliance by Distributor with applicable laws, rules and regulations. 
 (c) A
Party shall not carry out the audits provided for under this Section 5.9 more than once per year unless there is reasonable cause for an additional audit (including, but not limited to, following up any prior deficiencies noted in the course of
prior audits or notification of an issue in any of the foregoing areas). Each Party performing an inspection or audit shall conduct it in a manner that minimizes disruption of the business operations of the Party being audited. 

(d) If an inspection or audit reveals that the facilities do not satisfy the requirements above in all material respects, then the
Party conducting the audit (the “Auditing Party”) shall promptly provide to the other Party (the “Audited Party”) written notice of such fact, which notice shall contain in reasonable detail the deficiencies found in the
facilities and, if practicable, those steps the Auditing Party believes should be undertaken in order to remedy such deficiencies. The Parties shall discuss in good faith the proposed deficiencies and, to the extent there is agreement on the
proposed deficiencies, the Audited Party shall use Commercially Reasonable Efforts to remedy such deficiencies, or implement a plan to remedy such deficiencies, as soon as reasonably practical following receipt of the notification thereof;
(provided, however, that in the case of an audit by Distributor of a Third Party Vendor’s facilities, Manufacturer shall discuss any such noted deficiencies with the applicable Third Party Vendor and shall request that the Third Party Vendor
implement reasonably appropriate corrective measures). 
 (e) Distributor’s rights under this Section 5.9 are
subject to the rights and obligations of Manufacturer under its Third Party Vendor agreements. [***] 
 5.10
[***] 
 5.11 Quality Agreement. Manufacturer and Distributor shall negotiate in good faith to enter
into a quality agreement (the “Quality Agreement”) with additional customary terms and conditions, consistent with the terms of this Agreement, within thirty (30) days following the Effective Date. 

ARTICLE 6 

PACKAGING AND REMINDER MATERIALS 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 18 

 6.1 Packaging. All Products supplied to Distributor hereunder shall be in
finished packaged form. Manufacturer shall provide Distributor with sufficient information concerning packaging and labeling components for Distributor to develop appropriate artwork, and Distributor shall design such artwork and supply it to
Manufacturer. Manufacturer shall produce all package and labeling materials to be used for the Products (including print-ready artwork with Distributor’s NDC#). Any changes to the packaging and labeling specifications requested by Distributor
after the First Commercial Sale of a Product shall require the prior written consent of Manufacturer. If Manufacturer consents to such changes, such changes will be at Distributor’s cost and expense (including any costs associated with
inventory or component write-off), in accordance with Section 4.2(b). Distributor shall clearly identify Manufacturer as the manufacturer of the Product on all packaging materials unless otherwise requested by Manufacturer. 

6.2 Promotional Materials. Unless otherwise agreed by Manufacturer, Distributor shall have the right to use only the
following promotional materials in connection with the marketing of the Products: professional purchasing information consisting of a trade fact sheet (containing a product profile using standard drug listing information) and a related flyer
(containing information from the trade fact sheet and a statement that the Products are an authorized generic version of the Branded Products); trade show graphics; and a page on Distributor’s publicly available web site comparing the Products
to the Branded Products. All promotional materials prepared by Distributor in connection with the Products shall comply with all applicable laws, rules and regulations, including without limitation, Section 502(n) of the Act and 21 CFR Part
200.200 and Part 202. Distributor shall be solely liable for all statements and representations in Distributor’s promotional materials that are inconsistent with the labeling for the Branded Products, or which otherwise violate any applicable
laws or regulations. Manufacturer shall have final approval authority for all promotional materials. Distributor shall submit to Manufacturer for its approval all such materials for the Products prior to their use by Distributor, and Manufacturer
shall respond to any requests for approval within ten (10) business days of receipt; provided, however, that Manufacturer shall not have any approval rights over any portion of Distributor’s promotional materials to the extent they relate
solely to the resale pricing of the Products or any potential competition between Distributor and Manufacturer, and Distributor shall redact any such information from its submissions to Manufacturer. Manufacturer shall be responsible for submitting
promotional materials to FDA/DDMAC as required by law under the NDA for the Branded Products. For purposes of this Agreement, “promotional materials” includes all labeling and reminder materials (consisting of trade show graphics) as
defined in 21 CFR Section 200.200 and Section 202.1(e)(2), as well as any other applicable provisions of the Act or applicable regulations. 
 6.3 Sampling. Distributor shall not provide or cause to be provided any samples of Products to any Third Party for use by consumers. 

ARTICLE 7 

REGULATORY; RECALLS 
 7.1 Adverse Drug Experiences; FDA Audits; etc.  

  
 19 

 (a) Notification. 

(i) Adverse Drug Experiences. Distributor shall notify Manufacturer of any Adverse Drug Experience with respect to a
Product within one (1) business day of the time such Adverse Drug Experience becomes known to Distributor or its employees or any of their Affiliates and such reports shall be made in accordance with and in the manner set forth on the form
attached hereto as Exhibit 7.1. 
 (ii) Complaints. Each Party shall refer any complaints, including
medical complaints and drug product complaints, that it receives concerning any Product in the Territory to the other Party within ninety-six (96) hours of receiving such complaint; provided that all complaints concerning suspected or actual
product tampering, contamination or any Product that is out-of-specification shall be delivered within twenty-four (24) hours of receiving such complaint, and any complaint that includes a possible Adverse Drug Experience shall be reported to
Manufacturer in accordance with Section 7(a)(i). 
 (b) Disclosure. Except as required by applicable laws,
Distributor shall not disclose any information concerning any Adverse Drug Experience or any complaint concerning any Product to any Third Party without the prior written consent of Manufacturer. 

(c) Training. Distributor shall provide its employees and agents with adequate training in order to ensure compliance with
the reporting requirements under Section 7.1(a). For purposes of training its personnel as to what an Adverse Drug Experience is, a Distributor shall use the following definition: 

An Adverse Drug Experience is any adverse event, including any untoward, unwanted or “bad” thing that happens to an individual
during or after any use of the Product, even if a particular event is not thought to be related to Product use (e.g., getting hit by a car), and even if an event is mentioned in the Product labeling (e.g., what is sometimes called a “side
effect”). Reports of exposure during pregnancy, drug overdose, drug or product abuse, unanticipated beneficial effects, inadvertent or accidental exposure, drug exposure through breast feeding, medication error, adverse drug experience
occurring from withdrawal of the drug or product and failure of pharmacological action (e.g., it doesn’t work) should also be considered Adverse Drug Experiences for internal reporting purposes. An Adverse Drug Experience is also sometimes
referred to as an adverse drug reaction, adverse event or side effect. 
 (d) Reporting. Manufacturer shall be
solely responsible for Adverse Drug Experience reporting for the Products. Manufacturer shall comply with applicable FDA requirements concerning Adverse Drug Experience reporting for the Products, including 21 C.F.R. Section 314.80. 

(e) Pharmacovigilance. As part of the Quality Agreement, Manufacturer and Distributor shall negotiate in good faith
additional customary terms and conditions relating to pharmacovigilance, consistent with the terms of this Agreement. 

  
 20 

 7.2 Recalls. 

(a) If a recall of any Product sold by or on behalf of Distributor is required or recommended by the FDA, or if a recall,
suspension or other withdrawal of any Product sold by or on behalf of Distributor is deemed advisable by Distributor and Manufacturer, such recall, suspension or other withdrawal shall be implemented and administered by the Parties in a manner that
is appropriate and reasonable under the circumstances and in conformity with accepted trade practices and any requests, recommendations, or orders of the FDA. Each Party shall cooperate with the other Party to effectuate such recall, suspension or
other withdrawal. 
 (b) In the absence of an order or recommendation of the FDA, if the Parties are unable to agree upon
a Product recall, suspension or other withdrawal, Manufacturer shall make the final decision on all matters related to the recall, suspension or other withdrawal (including matters relating to the method of implementation), except that Distributor
may implement and administer a recall or suspension of Product distributed by it if it reasonably believes, based on the advice of outside regulatory counsel and after good faith discussion with Manufacturer, that a failure to administer a recall or
suspension would pose health risks to the public. 
 (c) Manufacturer shall pay all Recall Costs and Expenses in
connection with a recall under this Section 7.2, except that Distributor shall bear such Recall Costs and Expenses to the extent such recall is implemented as a result of Distributor’s negligence or breach of its obligations under this
Agreement. As used in this Section 7.2, the term “Recall Costs and Expenses” means only (i) actual expenses or obligations to Third Parties for such recall (but not including payments for lost profits or economic loss),
(ii) the costs and expenses of notifying customers, (iii) the costs and expenses associated with shipment of the recalled units of Product, and (iv) the costs and expenses of destroying and replacing such recalled units or, in the
case of Manufacturer, reimbursing Distributor for the Invoice Supply Price paid with respect to the recalled units if such units cannot be replaced (and [***] paid or payable by Distributor if Distributor has sold or transferred the Capsule
Product to a Third Party). 
 (d) Distributor undertakes to use Commercially Reasonable Efforts to establish a tracing
and recall system which will enable Distributor, to the extent reasonably possible, to identify, as quickly as possible, customers within the Territory who have been supplied with Product of any particular batch, and to recall such Product from such
customers. Distributor also agrees to reasonably coordinate with Manufacturer and its third party reverse logistics vendor from time to time during the Term to prepare for any potential recall, suspension or other withdrawal. 

7.3 Information. Within fifteen (15) days after Manufacturer’s request from time to time, Distributor shall
provide Manufacturer all information in Distributor’s possession or control necessary for Manufacturer to comply with FDA reporting requirements. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 21 

 ARTICLE 8 
 REPRESENTATIONS AND WARRANTIES 
 8.1 Manufacturer Representations and
Warranties. Manufacturer represents and warrants to Distributor that, as of the Effective Date: 
 (a) all
necessary corporate and other authorizations, consents and approvals which are necessary or required for it to enter into of this Agreement have been duly obtained; 
 (b) the entering into of this Agreement by Manufacturer shall not (i) violate any provision of law, statute, rule or regulation or any ruling, writ, injunction, order, judgment or decree of
any court, administrative agency or other governmental body to which Manufacturer is subject, or (ii) conflict with or result in any breach of any of the terms, conditions or provisions of, any agreement to which Manufacturer or any of its
Affiliates is a party or by which it or its Affiliates or any of its or their properties or assets is bound or affected; 

(c) the Products will be sold to Distributor free and clear of all liens, claims and encumbrances of any nature; 

(d) to the best of its knowledge, the manufacture, use and sale of the Products does not infringe the patents of any Third Party
in the Territory; and 
 (e) it has not granted any license, right or interest in or to the Products, or any method of
manufacture thereof, to any Third Party that would conflict with the rights being granted to Distributor under this Agreement. 

(f) Manufacturer has supplied Distributor with a correct and complete copy of the agreements between Manufacturer and the
University of Missouri that govern the calculation of License Fees and Royalties payable by Manufacturer to the University of Missouri, and there are no other agreements that govern such calculation. 

8.2 Distributor Representations and Warranties. Distributor represents and warrants to Manufacturer as of the Effective
Date that: 
 (a) all necessary corporate and other authorizations, consents and approvals which are necessary or
required for it to enter into this Agreement have been duly obtained; and 
 (b) the entering into of this Agreement by
Distributor shall not (i) violate any provision of law, statute, rule or regulation or any ruling, writ, injunction, order, judgment or decree of any court, administrative agency or other governmental body, or (ii) conflict with or result
in any breach of any of the terms, conditions or provisions of, any agreement to which Distributor, or any of its Affiliates is a party or by which it or its Affiliates or any of their properties or assets is bound or affected. 

8.3 Disclaimer of Warranties. 

  
 22 

 (a) EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY OTHER
REPRESENTATION OR WARRANTY TO THE OTHER PARTY OF ANY KIND INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
 (b) NEITHER PARTY MAKES ANY WARRANTIES, EXPRESS OR IMPLIED, CONCERNING THE SUCCESS OF THE COMMERCIAL EXPLOITATION OF THE PRODUCTS. 

8.4 Limitations of Liabilities. 
 (a) Limitation on Certain Damages. EXCEPT FOR AND ONLY TO THE EXTENT OF ANY AMOUNTS PAID TO A THIRD PARTY RESULTING IN AN INDEMNIFIABLE CLAIM HEREUNDER AND IN THE CASE OF BREACH OF ARTICLE
11, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, INDIRECT, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND (INCLUDING, WITHOUT LIMITATION, LOST PROFITS, BUSINESS, OR GOODWILL) IN CONNECTION WITH ANY PRODUCTS SUPPLIED
OR TO BE SUPPLIED HEREUNDER, OR ANY OTHER MATTER COVERED BY THIS AGREEMENT, REGARDLESS OF WHETHER SUCH LIABILITY IS BASED ON BREACH OF CONTRACT, TORT, STRICT LIABILITY, BREACH OF WARRANTY, OR ANY OTHER THEORY, EVEN IF SUCH PARTY HAS BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES. 
 (b) Maximum Aggregate Liability. EXCEPT FOR AND ONLY TO THE EXTENT OF ANY
AMOUNTS PAID TO A THIRD PARTY RESULTING IN AN INDEMNIFIABLE CLAIM HEREUNDER, OBLIGATIONS UNDER SECTIONS 5.6 OR 5.7 (WHICH ARE SUBJECT TO SECTION 5.8) OR SECTION 7.2, AND ACCRUED AND UNPAID AMOUNTS DUE UNDER ARTICLE 3, IN NO EVENT SHALL EITHER
PARTY’S MAXIMUM AGGREGATE LIABILITY TO THE OTHER PARTY OR ANY OTHER PERSON WITH RESPECT TO ANY AND ALL CLAIMS CONCERNING THE PRODUCTS OR ANY OTHER MATTER COVERED BY THIS AGREEMENT, REGARDLESS OF THE FORM OF ACTION, EXCEED [***].

 (c) Allocation of Risks. The limitation of liability set forth in this Article 8 reflects a deliberate and
bargained for allocation of risks between Distributor and Manufacturer and is intended to be independent of any exclusive remedies available under this Agreement, including any failure of such remedies to achieve their essential purpose. 

(d) Essential Part of the Bargain. The Parties acknowledge that the limitations of liability set forth in this Article 8
are an essential element of this Agreement between the Parties and that the Parties would not have entered into this Agreement without such limitations of liability. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 23 

 ARTICLE 9 
 INDEMNIFICATION 
 9.1 Indemnification. In order to distribute
among the Parties the responsibility for claims arising out of this Agreement, and except as otherwise specifically provided for herein, the Parties agree as follows: 
 (a) Manufacturer agrees to defend and indemnify and hold Distributor harmless against any and all Third Party claims, demands, suits or proceedings, and all associated expenses, recoveries and
damages, including court costs and reasonable attorneys fees and expenses, arising out of, based on, or caused by (i) the breach by Manufacturer of any representation, covenant or warranty contained in this Agreement, (ii) any personal
injury (including death) caused by the use of Products, (iii) any claim that the sale of the Products (including, without limitation, the patents used in connection with making, using or selling the Products) infringes the intellectual property
rights of a Third Party, (iv) any certification filed with the FDA by a Third Party with respect to a Competitive Product under and pursuant to 21 U.S.C. Section 355(j)(2)(A)(vii)(IV) of the Act, or (v) any governmental investigation
or proceeding (administrative or otherwise) or Third Party claim relating to a potential or actual settlement agreement between Manufacturer and a Third Party that plans to market or is marketing a Competitive Product, except in the case of each of
subsections (i), (ii) or (iii) hereof, to the extent that such claims, suits, proceedings, expenses, recoveries or damages arise from or are aggravated by acts of or failure to act by Distributor, including without limitation, any breach
by Distributor of this Agreement. 
 (b) Distributor agrees to defend and indemnify and hold Manufacturer harmless
against any and all Third Party claims, demands, suits, proceedings, and all associated expenses, recoveries, and damages including court costs and reasonable attorneys fees and expenses, arising out of, based on, or caused by
(i) Distributor’s performance under this Agreement, including the storage, sale, shipment, promotion or distribution of the Products by or on behalf of Distributor, or (ii) the breach by Distributor of any representation, covenant or
warranty contained in this Agreement, except in each case to the extent that such claims, suits, proceedings, expenses, recoveries or damages arise from or are aggravated by acts of or failure to act by Manufacturer, including without limitation,
any breach by Manufacturer of this Agreement. 
 9.2 Procedures. In connection with any claim for indemnification
under Section 9.1(a) or (b), (i) the Party seeking indemnification shall provide the other Party with reasonably prompt written notice of any claim or action for which it seeks indemnification, (ii) the indemnifying Party shall have
the right to control the defense and settlement of any such claim or action (but only to the extent no injunctive relief is being sought), and (iii) the indemnified Party shall reasonably cooperate and provide reasonable assistance in
connection with the defense and settlement of any such claim or action. 

  
 24 

 ARTICLE 10 
 TERM AND TERMINATION 
 10.1 Term. This Agreement shall
commence as of the Effective Date and shall continue for a period of five (5) years after the first Commencement Date to occur, unless terminated earlier as provided below (the “Initial Term”). This Agreement will automatically renew
for additional one (1) year terms (each, a “Renewal Term”) unless either Party elects not to renew this Agreement by written notice to the other Party, which notice must be provided at least six (6) months prior to the expiration
of the Initial Term or the applicable Renewal Term, as the case may be. The Initial Term and any applicable Renewal Term are collectively referred to herein as the “Term.” 

10.2 Termination by Manufacturer. 
 (a) Delay in First Commercial Sale. If there has not been a First Commercial Sale of at least one SKU of the Products before December 31, 2012, Manufacturer may terminate this
Agreement with respect to one or more SKUs of the Products at any time prior to the occurrence of a First Commercial Sale upon written notice to Distributor. 
 (b) Convenience. Manufacturer may terminate this Agreement (i) with respect to a Product SKU, at any time prior to the First Commercial Sale of that Product SKU for any reason upon
written notice to Distributor, provided Manufacturer gives the notice before it gives any written approval under Section 2.1(c) for Distributor to engage in pre-booking activities, (ii) with respect to a Product SKU, at any time following
the First Commercial Sale of that Product SKU upon thirty (30) days written notice to Distributor in the event that a Competitive Product (with respect to that Product SKU) that was previously launched is no longer available, provided that this
clause (ii) shall not apply with respect to Capsule Product on account of a Competitive Product not being available as of the Amended and Restated Effective Date, but shall apply in the event a Competitive Product is subsequently re-introduced
and then is no longer available, and (iii) in whole or on a Product SKU basis, at any time following the First Commercial Sale of a particular Product SKU for any reason upon nine (9) months’ written notice to Distributor. 

 (c) Distributor Change of Control. If Distributor agrees to become or otherwise becomes subject to any Change
of Control, Distributor shall so notify Manufacturer, in writing, within ten (10) days. Manufacturer may terminate this Agreement upon sixty (60) days written notice to Distributor after a Change in Control of Distributor, which notice
must be given no later than thirty (30) days after Distributor gives Manufacturer written notice of the Change of Control, or if no notice is provided by Distributor, at any time following such Change of Control. 

(d) Non-availability of Competitive Product after Launch. If one or more Competitive Products with respect to a Product are
launched and all such Competitive Products are no longer available, Manufacturer may, in addition to the other rights set forth in this Article 10, suspend (but not terminate) this Agreement immediately with respect to such Product or Products upon
written notice to Distributor; provided that such suspension may not be implemented by Manufacturer with respect to Capsule Product on account of Competitive 

  
 25 

 
Product not being available as of the Amended and Restated Effective Date, but such suspension may be implemented in the event a Competitive Product is subsequently re-introduced and then is no
longer available. Such suspension will continue until a Competitive Product is again available and Manufacturer notifies Distributor to commence distributing and marketing the Product or Products. 

(e) Additional Termination Right for Capsule Product. Manufacturer may terminate this Agreement with respect to the Capsule
Product upon thirty (30) days written notice to Distributor (i) if at any time after the date six (6) months after the Amended and Restated Effective Date Manufacturer determines to cease distribution and sales of an authorized
generic version of such Capsule Product through a contracted distributor or at all, or (ii) in connection with any settlement of patent litigation relating to the Capsule Product (which may or may not include continued sale of an authorized
generic version of such product). In the event a Competitive Product is available at the time of, or is reasonably anticipated to be available shortly following, such termination by Manufacturer under this Section 10.2(e), the parties shall
negotiate in good faith and agree to an appropriate and equitable solution to mitigate penalties incurred or expected to be incurred by Distributor under its customer contracts as a result of such termination by Manufacturer, provided that such
penalties are reasonable and customary in the generic pharmaceutical distribution industry. 
 10.3 Termination by
Distributor. 
 (a) Delayed Commencement Notice or Failure to Deliver Launch Quantities.
Distributor may terminate this Agreement with regard to a particular SKU of the Products upon prior written notice to Manufacturer if (i) Manufacturer fails to deliver a Commencement Notice with respect to that SKU within sixty (60) days
after the launch by a Third Party in the Territory of a Competitive Product (with respect to that Product SKU), or (ii) Manufacturer delivers a Commencement Notice within such sixty (60) day period, but Manufacturer fails to deliver to
Distributor launch quantities of the applicable SKU of the Products in compliance with this Agreement and such failure prevents Distributor from making the First Commercial Sale of the applicable SKU of the Products within such sixty (60) day
period. 
 (b) Significant Selling Price Decrease. If Distributor’s net selling price of an SKU of the
Products decreases to less than [***] of the Invoice Supply Price ([***] during Periods 1 and 2) for that SKU of the Products sold during any [***] day period, then Distributor may provide written notice
(the “Supply Notice”) to Manufacturer of such occurrence and a calculation of the Invoice Supply Price ([***] during Periods 1 and 2) for such SKU that would have been necessary to avoid such occurrence. If Distributor and
Manufacturer fail to negotiate a new Invoice Supply Price ([***] during Periods 1 and 2) for the applicable SKU acceptable to both Parties within thirty (30) days after delivery of the Supply Notice, either Party shall have the
right to terminate this Agreement with regard to the applicable SKU immediately upon written notice delivered within fifteen (15) days after such initial thirty (30) day period; provided however, that with respect to termination of this
Agreement with regard to Capsule Product during Period 1 or Period 2, Distributor shall provide to Manufacturer at least [***] days advance written notice of termination; and provided, further, that Distributor shall not have a
termination right under this Section 10.3(b) if prior to the expiration of such thirty (30) day 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 26 

 
period Manufacturer notifies Distributor that it is reducing the Invoice Supply Price ([***] during Periods 1 and 2) for future deliveries of the applicable SKU of the Products to
the amount specified for such SKU in Distributor’s Supply Notice to Manufacturer under this Section 10.3(b). For purposes of this Section 10.3(b), the Invoice Supply Price [***] of the Products sold by Distributor and
Distributor’s selling price of those Products shall be determined on a SKU by SKU basis and any new Invoice Supply Price [***] mutually agreed pursuant to this Section 10.3(b) shall be applied [***] 

(c) Continuing Suspension. If Manufacturer suspends this Agreement under Section 10.2(d) and the suspension lasts for
more than two (2) years, Distributor may terminate this Agreement upon written notice to Manufacturer. 
 10.4
Termination by Non-Defaulting Party upon Event of Default. Upon the occurrence of an Event of Default, in addition to all rights and remedies provided by applicable law, the non-defaulting Party in its sole discretion may terminate this
Agreement upon thirty (30) days’ prior notice to the defaulting Party. For purposes of this Section 10.4, the occurrence of any one or more of the following acts, events or occurrences shall constitute an “Event of Default”
under this Agreement: (a) either Party becomes the subject of a Bankruptcy Event; or (b) either Party fails to cure any material breach of its obligations under this Agreement within sixty (60) days after written notice of the breach
from the other Party. In the case of Manufacturer’s supply obligations under Section 5.5, an “Event of Default” shall be deemed to have occurred if Manufacturer has failed to supply (i) at least [***] percent
([***]%) of firm purchase order quantities for [***] consecutive months; or (ii) at least [***] percent ([***]%) of firm purchase order quantities for a total [***] month
period; provided, however, that in such event, an “Event of Default” shall not be deemed to have occurred to the extent that (A) the failure to supply is a result of Product failing to meet the applicable Specifications or product
warranties (wherein Section 5.8 shall be the sole and exclusive remedy); or (B) Distributor has sufficient inventory to cover any shortfalls under purchase orders. 
 10.5 Termination by Mutual Agreement. In the event that the Parties mutually determine that the arrangements contemplated by this Agreement are no longer in the best interests of the Parties
or the Parties are not otherwise compatible, the Parties may at any time, by mutual written agreement, terminate this Agreement in its entirety or with regard to one or more Product SKUs. 

10.6 Termination for Withdrawal of NDA or Branded Products. Either Party shall have the right to terminate this Agreement
with regard to one or more Product SKUs upon thirty (30) days written notice to the other Party in the event of: (i) withdrawal of the NDA for the applicable Branded Products; (ii) withdrawal of the applicable Branded Products from
the market for medical or scientific concerns as to toxicity, safety or efficacy; or (iii) withdrawal of the applicable Branded Products upon the written request of any Regulatory Agency. 

10.7 Force Majeure Events. If either Party is prevented from performing any of its obligations hereunder due to any cause
which is beyond the non-performing Party’s reasonable control, including fire, explosion, flood, or other acts of God; acts, regulations, or laws of any government; war or civil commotion; strike, lock-out or labor disturbances; or failure of
public utilities or common carriers (a “Force Majeure Event”), such non-performing Party shall not be 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 27 

 
liable for breach of this Agreement with respect to such non-performance to the extent any such non-performance is due to a Force Majeure Event. Such non-performance will be excused for as long
as such event shall be continuing, provided that the non-performing Party gives prompt written notice to the other Party of the Force Majeure Event. Such non-performing Party shall exercise all Commercially Reasonable Efforts to eliminate the Force
Majeure Event and to resume performance of its affected obligations as soon as practicable. Should the event of Force Majeure continue unabated for a period of sixty (60) days or more, the Parties shall enter into good faith discussions
with a view to alleviating its affects or to agreeing upon such alternative arrangements as may be fair and reasonable having regard to the circumstances prevailing at that time, up to and including termination of the Agreement in whole or on a
Product SKU basis. 
 10.8 Statutory Rights. Distributor acknowledges that it is cognizant of certain state
statutes that impose on a wholesaler, distributor or importer specific duties and obligations with regard to the termination of a distribution agreement. Notwithstanding the rights conferred under those statutes to a distributor, Distributor hereby
waives its rights thereunder with respect to a valid termination pursuant to a right under this Agreement and in consideration of its appointment hereunder covenants not to sue Manufacturer, or submit a complaint to any Regulatory Agency or
governmental authority, in the event of the termination of this Agreement except for the purpose of enforcing Distributor’s rights under this Agreement. This Section in no way affects the enforcement rights of Distributor to recover amounts
earned pursuant to this Agreement. 
 10.9 Obligations Following Termination. 

(a) Cessation of Distribution Efforts. Upon expiration or termination of this Agreement for any reason, as of the date of
such expiration or termination (i) Distributor shall immediately stop all distribution, marketing and sales of the applicable SKU of the Products, and (ii) Distributor’s binding purchase commitments under Section 5.5(b) for the
applicable SKU of the Products shall be canceled automatically, except that in the case of termination by Distributor under Section 10.4 for Manufacturer’s Event of Default, Distributor may elect to complete the purchase of Products under
its binding purchase commitments and sell off its remaining inventory, subject to payment to Manufacturer therefor pursuant to Section 3.2 through and including 3.5. 
 (b) Repurchase of Inventory. Upon termination of this Agreement by Manufacturer under Section 10.2(b)(ii) or (iii) (Manufacturer’s convenience after First Commercial Sale),
10.2(c) (Manufacturer’s choice upon Distributor’s Change of Control), or 10.2(e) (Additional Termination Right for Capsule Product), by Distributor under Section 10.3(c) (Continuing Suspension) or 10.4 (Manufacturer’s Event of
Default), or by either Party under Section 10.3(b) (Significant Selling Price Decrease) or 10.6 (termination of NDA or withdrawal of Branded Products), Manufacturer shall purchase from Distributor, at the Invoice Supply Price paid for such
Products (and a credit for any Invoice Supply Price due but not yet paid), all inventory of Products then held by Distributor that has no less than [***] of remaining shelf life as of the date of termination (except that in no event
shall the Products to be purchased back from Distributor exceed [***] of inventory based on the average sales by Distributor for the [***] prior to the date of notice of termination) and except that the shelf life
requirement shall not apply in the case of termination under Section 10.3(c)), provided that Distributor has used its Commercially Reasonable Efforts to reduce the amount of inventory held at termination. In 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 28 

 
addition to the foregoing, upon termination of this Agreement by Manufacturer under Section 10.2(b)(ii) or (iii) (Manufacturer’s Convenience after First Commercial Sale) or 10.2(e)
(Additional Termination Right for Capsule Product), by Distributor under Section 10.3(c) (Continuing Suspension) or 10.4 (Manufacturer’s Event of Default), or by either Party under Section 10.6 (termination of NDA or withdrawal of
Branded Products), Manufacturer shall reimburse Distributor for [***] by Distributor under Section 5.1 for all inventory of Products purchased by Manufacturer under this Section 10.9(b) and [***] associated with
returning such inventory to Manufacturer. 
 (c) Return of Launch Quantities. Upon termination of this Agreement
under Section 10.2(a) (Delay in First Commercial Sale), 10.2(b)(i) (Manufacturer’s Convenience prior to First Commercial Sale), 10.3(a) (Delayed Commencement Notice or Failure to Deliver Launch Quantities), or 10.3(c) (Continuing
Suspension), Distributor shall promptly return all Products supplied by Manufacturer to Distributor, [***], and any outstanding invoices from Manufacturer for such Products shall be canceled automatically. 

(d) Application to Individual SKUs of Product. To the extent the applicable termination event applies to less than all of
the Products, then the provisions contained in this Section 10.9 shall apply only to the Product so affected. 
 10.10
Effects of Termination. Upon termination of this Agreement, (a) this Agreement shall thereafter have no effect, except as provided in Section 12.2, (b) payment obligations that have accrued and have been invoiced prior to
the date of termination shall remain due and payable in accordance with the terms of this Agreement, and payment obligations that have accrued but have not been invoiced as of the date of termination shall be invoiced and paid in full within thirty
(30) days of receipt of such invoice, (c) all rights and licenses granted by Manufacturer to Distributor shall immediately cease, and (d) except as otherwise set forth herein, neither Party shall be relieved from liability for any
breach of any representation, warranty or agreement hereunder occurring prior to such termination. 
 ARTICLE 11

 CONFIDENTIALITY, PUBLIC ANNOUNCEMENTS AND DISCLOSURE 

11.1 Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed by the Parties in
writing, until the later of (i) the termination of this Agreement or (ii) ten (10) years after the date of disclosure, each of Distributor and its Affiliates, on the one hand, and Manufacturer and its Affiliates on the other (the
“Recipient”), receiving or learning of any Confidential Information of the other Party (the “Disclosing Party”) in connection with this Agreement or the [***], shall keep such information confidential
and shall not publish or otherwise disclose or use it for any purpose other than as provided for in this Agreement, except to the extent that it can be established by the Recipient that the Confidential Information: 

(a) Was already known to the Recipient (other than under an obligation of confidentiality) at the time of receipt by the
Recipient, and the Recipient can so demonstrate by documentary evidence to that effect; 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 29 

 (b) Was generally available to the public or otherwise part of the public domain at
the time of its disclosure to the Recipient; 
 (c) Became generally available to the public or otherwise part of the
public domain after its disclosure and other than through any act or omission in breach of a confidentiality obligation of the Recipient; 
 (d) Was disclosed to the Recipient (other than under an obligation of confidentiality) by a Third Party who had no obligation to the Disclosing Party not to disclose such information to others; or

 (e) Was independently discovered or developed by the Recipient without the use of the Confidential Information of the
Disclosing Party, and the Recipient can so demonstrate by documentary evidence to that effect. 
 11.2 Authorized
Disclosure. Notwithstanding the foregoing, a Recipient may disclose Confidential Information of the Disclosing Party to a Third Party to the extent such disclosure is reasonably necessary to: 

(a) Prosecute or defend litigation; 
 (b) Effectively exercise rights granted to the Recipient hereunder; or 

(c) Comply with applicable governmental laws and regulations, orders, rulings, guidance documents, pronouncements, filing
requirements and the like. 
 In the event a Recipient shall deem it necessary to disclose, pursuant to this Section 11.2, Confidential
Information of the Disclosing Party, the Recipient shall, to the extent possible, give reasonable advance notice of such disclosure to the Disclosing Party, shall use reasonable efforts to minimize the scope of such disclosure, and shall cooperate
with the Disclosing Party to take reasonable measures to ensure confidential treatment of such information, including, but not limited to, by requiring the Third Party to whom the Confidential Information is disclosed to agree in writing to maintain
such information in confidence and to use it only for the purposes for which it is disclosed. 
 11.3 SEC Filings.
Either Party may disclose the terms of this Agreement to the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with applicable laws, including, without limitation, the rules and regulations promulgated by the
United States Securities and Exchange Commission. Notwithstanding the foregoing, before disclosing this Agreement or any of the terms hereof pursuant to this Section 11.3, the Parties will reasonably consult with one another on the terms of
this Agreement to be redacted in making any such disclosure. If a Party discloses this Agreement or any of the terms hereof in accordance with this Section 11.3, such Party agrees, at its own expense, to seek confidential treatment of portions
of this Agreement or such terms, as may be reasonably requested by the other Party. 
 11.4 Public Announcements.
Neither Manufacturer nor Distributor shall issue any press release or make any other public announcement or otherwise disclose or announce this Agreement, the existence thereof, or the terms, conditions or subject matter hereof, without the

  
 30 

 
prior written approval of the other Party, including without limitation, approval of the specific text of such release, announcement or statement; provided, that to the extent Manufacturer or
Distributor, as the case may be, shall have received written advice of counsel that it is required to make an announcement or furnish a statement pursuant to the laws of its jurisdiction of incorporation or any jurisdiction in which any of its
securities are publicly traded or the rules of any stock exchange upon which its securities are listed or any registered securities quotation system on which such securities are traded, it shall be permitted, after providing the other Party with a
copy of such announcement or statement at least five (5) business days (or such shorter time as may be set forth in such written advice of counsel, but in no event less than one (1) business day) prior to its proposed issuance or
submission, and after discussing such announcement or statement with the other Party and considering in good faith the modifications to such announcement or statement proposed by the other Party, to do so even if it has not obtained the approval of
the other Party. Any determination that disclosure by a Party pursuant to this Section 11.4 is required shall be consistent with such Party’s past practices with respect to such disclosure. 

11.5 Injunctive Relief. Anything herein to the contrary notwithstanding, the Parties acknowledge that any breach of the
provisions of this Article 11 could cause irreparable harm and significant injury, which may be difficult to ascertain, and are not susceptible to monetary damages. Accordingly, the Parties agree that the Disclosing Party shall have the right to
seek the issuance of an ex parte restraining order or injunction to prevent any breach or continuing violation of the Recipient’s obligations hereunder, in addition to (and not in substitution of) any other remedies that may be available to the
Disclosing Party at law or in equity. 
 ARTICLE 12 

MISCELLANEOUS 
 12.1 Insurance. Each Party agrees to procure and maintain in full force and effect during the term of this Agreement and for as long as the Products sold by or on behalf of Distributor are
in the marketplace valid and collectible insurance policies in connection with this Agreement, which policies shall provide for the type of insurance and amount of coverage described in Exhibit 12.1 to this Agreement. Upon written request, a
Party shall provide the other a certificate of coverage or other written evidence reasonably satisfactory of such insurance coverage. 
 12.2 Survival. The provisions of Articles 7, 9, 10, 11 and 12 and those provisions of this Agreement dealing with rights and obligations after termination of this Agreement shall survive
termination of this Agreement to the extent necessary to give effect to such provisions. 
 12.3 Independent Contractor
Status; No Joint Venture or Partnership. Neither Party shall have any authority to obligate the other in any respect or to hold itself out as having any such authority. All personnel of Manufacturer shall be solely employees of Manufacturer
and shall not represent themselves as employees of Distributor, and all personnel of Distributor shall be solely employees of Distributor and shall not represent themselves as employees of Manufacturer. Nothing herein shall be deemed to create a
partnership or joint venture between the Parties. 

  
 31 

 12.4 Binding Effect; Benefits; Assignment. 

(a) This Agreement shall inure to the benefit of and be binding upon the Parties hereto and their respective permitted successors
and assigns. Nothing contained herein shall give to any other person any benefit or any legal or equitable right, remedy or claim. 
 (b) This Agreement shall not be assignable by Distributor without the prior written consent of Manufacturer, except that, subject to Section 10.2(c), Distributor shall be permitted to assign
this Agreement without the prior written consent of Manufacturer to a Person acquiring all or substantially all of Distributor’s assets or voting stock. Such assignment shall be subject to the assignee agreeing in writing to assume the benefits
and obligations of this Agreement. Distributor shall provide Manufacturer prompt notice of any such sale, or other Change of Control, of Distributor promptly following consummation thereof. 

(c) This Agreement shall not be assignable by Manufacturer without the prior written consent of Distributor, except that
Manufacturer shall be permitted to assign this Agreement without the prior written consent of Distributor to a Person acquiring all or substantially all of Manufacturer’s assets or voting stock or to a Person purchasing the NDA with respect to
a Branded Product. Such assignment shall be subject to the assignee agreeing in writing to assume the benefits and obligations of this Agreement. Manufacturer shall provide Distributor prompt notice of any such sale, or other Change of Control, of
Manufacturer promptly following consummation thereof. 
 12.5 Entire Agreement; Amendments. This Agreement,
including all Exhibits, and the [***] and the Quality Agreement constitute the entire agreement between the Parties with respect to the subject matter of this Agreement and all prior agreements, understandings, promises and
representations, whether written or oral, with respect thereto are superseded hereby. Each of the Parties acknowledges that in deciding to enter into this Agreement and to consummate the transaction contemplated hereby none of them has relied upon
any statements or representations, written or oral, other than those explicitly set forth herein or therein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing
and signed by the respective authorized officers of the Parties. 
 12.6 Severability. In the event that any
provision of this Agreement would be held in any jurisdiction to be invalid, prohibited or unenforceable for any reason, such provision, as to such jurisdiction, shall be ineffective, without invalidating the remaining provisions of this Agreement
or affecting the validity or enforceability of such provision in any other jurisdiction. Notwithstanding the foregoing, if such provision could be more narrowly drawn while maintaining the intent of the Parties, so as not to be invalid, prohibited
or unenforceable in such jurisdiction, it shall, as to such jurisdiction, be so narrowly drawn, without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.

 12.7 Remedies. Unless otherwise expressly provided, all remedies hereunder are cumulative, and in addition to
any other remedies provided for by law and may, to the extent permitted by law, be exercised concurrently or separately, and the exercise of any one remedy 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 32 

 
shall not be deemed to be an election of such remedy or to preclude the exercise of any other remedy. 
 12.8 Notices. Any notice, request, consent or communication (collectively, a “Notice”) under this Agreement shall be effective if it is in writing and (i) personally
delivered, (ii) sent by certified or registered mail, postage prepaid, return receipt requested, (iii) sent by an internationally recognized overnight delivery service, with delivery confirmed, or (iv) sent by facsimile, with receipt
confirmed and hard copy delivered by regular mail; addressed as set forth in this Section 12.8 or to such other address as shall be furnished by either Party hereto to the other Party hereto. A Notice shall be deemed to have been given as of
(i) the date when personally delivered, (ii) seven (7) business days after being deposited with the United States Postal Service, certified or registered mail, properly addressed, return receipt requested, postage prepaid,
(iii) two business days after being delivered to said overnight delivery service properly addressed, or (iv) immediately upon receiving confirmation of receipt of the facsimile, as the case may be. All Notices shall specifically state:
(i) the provision (or provisions) of this Agreement with respect to which such Notice is given, and (ii) the relevant time period, if any, in which the Party receiving the Notice must respond. 

 

			
	If to Manufacturer:	 	
		 	Santarus, Inc.
		 	3721 Valley Centre Drive, Suite 400
		 	San Diego, CA 92130
		 	Attn: Gerald T. Proehl, President and CEO
		 	Fax: (858) 314-5701
		 	With a copy to:
		 	Santarus, Inc.
		 	3721 Valley Centre Drive, Suite 400
		 	San Diego, CA 92130
		 	Attn: Legal Affairs Department
		 	Fax: (858) 314-5702
	If to Distributor:	 	Prasco, LLC
		 	6125 Commerce Court
		 	Mason, OH 45040
		 	Attn: E. Thomas Arington, Chairman
		 	Fax: (513) 204-1120
		 	With a copy to:
		 	Scott Fruechtemeyer
		 	General Counsel
		 	Prasco, LLC
		 	6125 Commerce Court
		 	Mason, Ohio 45040

  
 33 

			
		 	     Fax: (513) 204-1120

 12.9 Waivers. The failure of either Party to assert a right hereunder or to insist upon
compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. The observance of any provision of this Agreement
may be waived (either generally or in any particular instance) only with the written consent of the waiving Party. 
 12.10
Counterparts. This Agreement may be executed in any number of counterparts, and execution by each of the Parties of any one of such counterparts will constitute due execution of this Agreement. Each such counterpart hereof shall be deemed
to be an original instrument, and all such counterparts together shall constitute but one agreement. 
 12.11
Headings. The article and section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 

12.12 Construction. The Parties expressly agree that any rule of construction to the effect that ambiguities are to be
resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement. 
 12.13
Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York. 
 [THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK.] 

  
 34 

 IN WITNESS WHEREOF, Distributor and Manufacturer intending legally to be bound hereby have
caused this Agreement to be duly executed as of the date first above written. 
  

			
	SANTARUS, INC.
		
	By:	 	 /s/ Gerald T. Proehl

	Name:	 	Gerald T. Proehl
	Title:	 	President and CEO
	
	PRASCO, LLC
		
	By:	 	 /s/ E. Thomas Arington

	Name:	 	E. Thomas Arington
	Title:	 	Chairman

  
 35

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00213-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00213-of-00352.parquet"}]]